Protocol I8B-MC-ITSM (b)
Evaluation of LY900014 in a Medtronic Pump  
[STUDY_ID_REMOVED]
Approval Date: 13-Apr-2019
I8B - MC- IT SM  (b )C l in ica l  P ro toco l Page  1
LY900014P ro toco l  I8B - MC- ITSM(b )
Eva lua t iono f  LY900014  in  a  Med t ron ic  Pump
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th is  documen t  is  con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies  and  
shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lved  in  the  c l in ica l  inves t iga t ion  o f  
( LY900014) ,  un less  s uch  pe rsons  a re  bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  
and  Company  o r  i ts  subs id ia r ies.   
No te  to  Regu la to ry  Au tho r i t ies :  Th is  documen t  may  con ta in  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .  E l i  L i l ly  and  
Company  reques ts  consu l ta t ion  rega rd ing  re lease / redac t ion  p r io r  to  any  pub l ic  re lease .  In  
the  Un i ted  S ta tes ,  th i s  do cumen t  is  sub jec t  to  F reedom  o f  In fo rma t ion  Ac t  (FO IA )  
Exemp t ion  4  and  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  
app rova l  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies .
App ro va l  Da te :  13 -Ap r -2019  GMTLY900014
E l i  L i l l y  and  Compan y
Ind ianapo l is ,  Ind iana  USA  4 6285
P ro to co l  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y  on  24  O c tobe r  2018 .
Amendmen t  (a )  E lec t ron ica l ly  S igned  and  App roved  by  L i l ly  on  24  Janua r y  2019 .
Amendmen t  (b)  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y  on  da te  p ro v ided  be low.
I8B-MC-ITSM (b) Clinical Protocol Page 2
LY900014Table of Conten ts
Section Page
Protocol  I8B-MC-ITSM (b) Evaluation of LY900014 in a Medtronic 
Pump.................................................................................................................................. 1
Table of Contents ........................................................................................................................ 2
1. Synopsis ............................................................................................................................. 6
2. Schedule of Act ivities......................................................................................................... 9
3. Introduction ...................................................................................................................... 14
3.1. Study  Rati onale ............................................................................................................ 14
3.2. Background .................................................................................................................. 14
3.3. Benefit/Risk Assessment .............................................................................................. 16
4. Object ives and Endpo ints.................................................................................................. 18
5. Study  Design ..................................................................................................................... 20
5.1. Overall Design ............................................................................................................. 20
5.2. Number of Participants .................................................................................................22
5.3. End of Study  Definit ion............................................................................................... 22
5.4. Scientific Rationale for Study  Design ........................................................................... 22
5.5. Justification for Dose ................................................................................................... 22
6. Study  Popul ation............................................................................................................... 23
6.1. Inclusio n Cri teria.......................................................................................................... 23
6.2. Exclusio n Cri teria........................................................................................................ 25
6.3. Lifest yle Restrict ions.................................................................................................... 28
6.4. Scree n Failures ............................................................................................................. 28
7. Treatments ........................................................................................................................ 29
7.1. Treatments Administered ............................................................................................. 29
7.1.1. Pac kaging and Labeling ....................................................................................... 29
7.1.2. Insulin Pumps ...................................................................................................... 30
7.1.2.1. Pump Bol us Delivery Speed ........................................................................... 30
7.1.2.2. Pump Bol us Delivery Time ............................................................................. 30
7.1.2.3. Pump Alerts .................................................................................................... 30
7.2. Method of Treatm ent Assignment ................................................................................ 30
7.3. Blinding ....................................................................................................................... 31
7.4. Dosage Modification .................................................................................................... 31
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 31
7.6. Treatment Compliance .................................................................................................32
7.7. Concomitant Therapy ................................................................................................... 32
I8B - MC- IT SM  (b )C l in ica l  P ro toco l Page  3
LY900014CC I7 .8 . T r e a tm e n ta f t e r  th e  End  o f  th e  S tudy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
7 . 8 . 1 . T r e a tm en t  a f t e r  S tudy Com p l e ti o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
7 . 8 . 2 . Sp e c ia l  T r e a tm en t  Con s i d e r a ti o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
8 . D is con t inu a t i on  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
8 .1 . D is con t inu a t i on  f rom  S tudy  T r e a tm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
8 . 1 . 1 . D is con t inu a t i on  o f  I n a d v e r t e n t l y  E n r o l l e d  P a t i e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
8 .2 . D is con t inu a t i on  f rom  th e  S tudy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
8 .3 . L o s t  t o  F o l l ow-u p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
9 . S tudy A s s e s sm en t s  and  P ro c edu r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
9 .1 . E f f i c a c y  A s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
9 . 1 . 1 . P r im ary  A s s e s sm en t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
9 . 1 . 2 . S e cond a ry A s s e s sm en t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
9 . 1 . 3 . A p p r o p r i a t e n e s s  o f  A s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
9 . 1 . 4 . S tudy P ro c edu r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 7
9 .1 .4 .1 . C o n t i n u o u s  G l u c o s e  M o n i t o r i n g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7
9 .1 .4 .3 . In f u s i on  S e t  Ch ang e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8
9 .1 .4 .4 . D iab e t e s  T r a in ing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
9 .2 . A dv e r s e  Ev en t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9
9 . 2 . 1 . S e r io u s  A d v e r s e  E v e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0
9 .2 .1 .1 . S u s p e c t e d  U n e x p e c t e d  S e r i o u s  A d v e r s e  R e a c ti o n s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
9 . 2 . 2 . Comp l a in t  H and l ing. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
9 .3 . T r e a tm e n t  o f  O v e r d o s e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 2
9 .4 . S a fe t y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
9 . 4 . 1 . Hyp o g l y c em i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
9 . 4 . 2 . S e v e r e  H y p o g l y c em i a. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3
9 . 4 . 3 . E l e c t r o c a r d i o g r am s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3
9 . 4 . 4 . V it a l  S ign s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 3
9 . 4 . 5 . L abo r a to ry T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3
9 . 4 . 6 . S a fe t y  Mon ito r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
9 .4 .6 .1 . P il o t  S a f e t y  A s s e s sm e n t. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4
9 .4 .6 .2 . H ep a t ic  S a f e t y  Mon ito r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
9 .5 . P h a rm a c o k i n e ti c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 .6 . P h a rm a c o d y nam i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 .7 . P h a rm a c o g e n om i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 .8 . B iom a rk e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
9 .9 . H e a l th  E conom i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6
1 0 .S t a t is t i c a l  C o n s i d e r a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7
I8B-MC-ITSM (b) Clinical Protocol Page 4
LY90001410.1. Sample Si ze Determinat ion.......................................................................................... 47
10.2. Popul ations for Analyses .............................................................................................. 47
10.3. Statistical Analyses ...................................................................................................... 47
10.3.1. General Statist ical Considerat ions........................................................................ 47
10.3.2. Treatment Comparabilit y..................................................................................... 48
10.3.2 .1. Patient Disposi tion.......................................................................................... 48
10.3.2.2. Patient Characteri stics.................................................................................... 48
10.3.2.3. Concomitant Therapy ..................................................................................... 49
10.3.2.4. Treatment Compliance .................................................................................... 49
10.3.3. Efficacy Analyses ................................................................................................ 49
10.3.3.1. Primary Analyses ........................................................................................... 49
10.3.3.2. Secondary  Analyses ........................................................................................ 49
10.3.3.3. Exploratory  Analyses ..................................................................................... 49
10.3.4. Safety Analyses .................................................................................................... 49
10.3.5. Subgroup Analyses .............................................................................................. 50
10.3.6. Interim Analyses .................................................................................................. 50
11. References ........................................................................................................................ 51
12. Appendices ....................................................................................................................... 52
I8B-MC-ITSM (b) Clinical Protocol Page 5
LY900014List of Tables
Table Page
Table ITSM.1. Schedule of Act ivities.................................................................................... 10
Table ITSM.2. Object ives and Endpo ints............................................................................... 18
Table ITSM.3. Treatment Regimens ...................................................................................... 29
List of Figures
Figure Page
Figure ITSM.1. Illustrati onof study  design for Clinical Protocol I8B -MC-ITSM. ................... 21
List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 53
Appendix 2. Clinical Laboratory  Tests ............................................................................... 56
Appendix 3. Study  Governance Considerat ions.................................................................. 57
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 62
Appendix 5. Classificat ion of Contraceptive Methods ........................................................ 63
Appendix 6. Protocol  Ammendment I8B-MC-ITSM (b) Evaluatio n of LY900014 in 
a Medtroni c Pum p......................................................................................... 64
I8B-MC-ITSM (b) Clinical Protocol Page 6
LY9000141.Synopsis
Title of Study: 
Evaluat ion of LY900014 in a Medtronic Pump.
Rationale : 
The aim of this study  is to com pare LY900014 and Humalog with respect to the percentage of 
time with glucose values within range (70 to180 mg/dL) when both are delivered via continuous 
subcutaneous insulin infusio n (CSII )by th e Medtroni c MiniMed 670G System while in Auto 
Mode as much as possible .  
Objective(s)/Endpoints:
Objectives Endpoints
Primary
1.To compare LY900014 and Humalog with respect 
to the percentage of time with sensor glucose 
values within range (7 0to180 mg /dL) 1. P ercentage of time with sensor glucose values 
between 70 and 180 mg/dL (both inclusive) ,
during the last 2 weeks of each 4-week treatment 
period
Secondary
2.To compare LY900014 with Humalog with respect 
to the mean sensor glucose2.Mean sensor gluc ose value (mg/ dL), during the 
last 2 weeks of each 4-week treatment period
3.To compare LY900014 and Humalog with respect 
to the percentage of time spent in Auto Mode3.Percentage of time (per week )spent in Auto Mode, 
during the last 2 weeks of each 4-week treatment 
period
4.To compare LY900014 with  Humalog with
respect to the percentage of time with sensor 
glucose values in hypoglycemic glucose ranges4. P ercentage of time with sensor glucose values 
<54mg/dLduring the last 2 weeks of each 4-week 
treatment period
5.To compare LY900014 and Humalog with respect 
to the rate of severe hypoglycemic events5.Rate (events/patient/100 years) of severe 
hypoglycemic events during each 4-week 
treatment period
6.To compare LY900014 and Humalog with respect 
to the rate and incidence of documented 
hypoglycemi a6.Rate (events/patient/year) and incidence (percent 
of patients with events) of documented 
hypoglycemic events ,during the last 2 weeks of 
each 4-week treatment period
7.To compare LY900014 and Humalog with
respect to total daily  dose7.Mean total daily bolus insulin dose and mean total 
daily  basalinsulin do se during the last 2 weeks of 
each 4-week treatment period
I8B-MC-ITSM (b) Clinical Protocol Page 7
LY900014Summary of Study Design:   
This study  is a prospecti ve, rando mized, double -blind, outpatient, 2 -treatm ent crossover, 
active -controlled study  conducted in pati ents wi th type 1 diabetes mellitus (T1D) currently  using 
an external CSII.  In the 2treatm entperiod s, LY900014 and Hum alogwill be delivered via the 
Medtroni c MiniMed 670G system  while in Auto Mode as much as possible .
The study  is desi gned to com pare LY900014 and Hum alogwith respect to the durati on of  time 
glucose values are wi thin range (70 to 180 mg/dL).  
Treatment Arms and Duration:   
The study  includes a 1- week screening period and a 2 -week lead -in period fo llowed by a 
2-period crossover, each period consisting o f 4 weeks of treatment, and a 2 -week post -treatm ent 
safet y follow-up.  
Following the l ead-in period, a 3 -day pilot safet y assessment will be conducted at a single site
forthe first 10 patients rando mized.  This pilot safety assessment will determine if the control 
algorithm in the Medtroni c 670G pum p can be used safely  in patients receiving LY900014.  
Number of Patients:
Approximately  50participants will be screened to achieve 42randomized for a total of 
approximately  36patients to complete the study .
Statistical Analysis:
Statistical analysis o f this study  will be the r esponsibilit y of Lilly or i ts desi gnee.   
Addit ional 
exploratory analyses of data will be conducted, as deemed appropriate.  
Unless otherwise specified, all  efficacy and safet y analyses will be conducted on the
Randomized Population.  Analyses of adverse events (AEs) will include all data collected during 
the course of the entire 4 -week treatm ent peri od for each treatm ent regardl ess of invest igational 
product (IP)use.  Analyses of hypoglycemia will be conducted from first dose to last dose of IP 
in each 4 -week treatm ent peri od.  Data collected during the safet y follow-up peri od will not be 
used for comparisons between treatments.  
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.10, and confidence inte rvals (CIs) will be calculated at 9 0%, 2 -sided.  
Treatment comparisons will be performed for the primary  object ive at the full significance level 
of 0.10. No multiplicityadjust ments will be made for the analysis o f secondary  and expl oratory  
objectives.
Baseline is defined as the last nonmissing measurement at or before the rando mizat ion visit
(Visit 4), unl ess otherwise spe cified and described in the SAP .
The primary  object ive of this study  is to com pare LY900014 and Humal ogwith respect to the 
percentage of time with sensor glucose (SG) values within range (70to180 m g/dL) , during the 
I8B-MC-ITSM (b) Clinical Protocol Page 8
LY900014last 2 weeks of each 4-week treatment period . The analysis model and select ion of covar iance
structure are described below.  
Unless otherwi se specified, a restricted maximum likelihood based, mixed -effect m odel repeated 
measures (MMRM) analysis will be used to analyze continuous longitudinal variables.  All the 
longitudinal observations at each scheduled postbaseline visit during the 4-week t reatm ent peri od 
for each treatm ent wil l be included in the analysis.  T he model will include the fixed -class effects 
of treatm ent, peri od, sequence, strata ( hemoglobin A1c; HbA1c [≤7.0
%, >7. 0%] and percentage 
of time wi th SGvalues from 70to 180 mg/dL over the 2 weeks prior to randomizat ion [≤75%, 
>75
%]), and the con tinuous, fixed covariate of baseline value.  The Kenward -Roger 
approximat ion will be used to estimate deno minator degrees of freedo m.  An unstructured 
covari ance structure will be used to mo del the wi thin-patient errors.  If this analysis fails to 
converge, a covariance structure of compound symmetry  without heterogeneous variances will 
be used. If the model still does not converge , 
strata m ay be deleted from  the m odel.  
Significance tests w ill be based on least squares means and Ty pe III tests.  SAS PROC MIXED 
will be used to perform the analysis.  
For categorical measures (such as incidence of AEs), summary statist ics will include sample 
size, frequency , and percentages.  Prescott’s exact test will be used for treatment comparisons, 
unless otherwise specified.
I8B-MC-ITSM (b) Clinical Protocol Page 9
LY9000142.Schedule of A ctivities
I8B-MC-ITSM (b) Clinical Protocol Page 10
LY900014Table ITSM .1. Schedule of A ctivities
Screen
ingLead -In Study Period I Study Period II Safety 
Follow -upEarly 
Termination
Visit 1 2 3a 4 5a6a 7 8a 9a 10 801 ET
Week of Treatment -3 -2 -1 0 * 2 4 * 6 8 10
Visit Window ( ±days) 0 3 3 3 3 3 3 3 3 3 7
Study Logistics
Informed consent signed X
Eligibility Criteria Reviewed X X
Randomization X
IWRS X X X X X X X X X X X X
Crossover X
Clinical Assessments
Patient demographics X
Medical history and preexisting conditions X
Physical exam ination /height X
ECG (12-lead) b X
Body weight X X X X X X X
Vital signs:  blood pressure/pulse rate c X X X X X X X
Concomitant medication X X X X X X X X X X X X
Adverse events X X X X X X X X X X X
Patient Education and Management 
Set standardized high/low glucose alerts X X X
At screening, record pump bolus delivery speed 
(Standard [1.5 U/min] or Quick [15 U/min]).  
At other office visits, confirm and record pump bolus delivery 
speed unchanged from screening.X X X X X
At screening, record infusion set cannula length (6mm or 
9mm).
If changed during study, record infusion set cannula length 
(6mm or 9mm) and reason for change.X X X X X
Reset pump ISF, CR, and AIT to randomization settings X
Change infusion set and reservoir at investigative site d X X X XeXe
I8B-MC-ITSM (b) Clinical Protocol Page 11
LY900014Screen
ingLead -In Study Period I Study Period II Safety 
Follow -upEarly 
Termination
Visit 1 2 3a 4 5a6a 7 8a 9a 10 801 ET
Week of Treatment -3 -2 -1 0 * 2 4 * 6 8 10
Visit Window ( ±days) 0 3 3 3 3 3 3 3 3 3 7
Review/Answer questions on Medtronic 670G System, 
Diabetes management education, carbohydrate counting, 
collecting 4 -point SMBG profiles, and review hypogly cemia 
and hypergly cemia management guidelines f,gX
Review total daily insulin dose h X
Review pump , CGM, and SMBG data for use in clinical 
decision making X X X X X X X X X X
Review/discuss hypoglycemia data X X X X X X X X X X
Remind patient to upload pump data toCareLink weekly X X X X X X X X X
Ancillary Supplies/Diaries/IP
Dispense infusion s ets, reservoirs, BG test strips , and 
ancillary  suppliesX X X X X
Dispense Study Diary X X X X
Collect Study Diary and review with patient X X X X X
Start open -label Humalog at office visit X
Start non -study rapid -acting analog insulin at office visit X
Dispense IP X X
Collect used and unused study drug andsupplies from patient X X X X
Transfer Diary Data to eCRF
Hypoglycemia events X X X X X X
Unplanned infusion set changes with noted reason (s) X X X X X
Transfer CareLink Data to eCRF
Pump settings: ISF, CR, AIT (used to start next treatment) X X X
Mean total daily bolus and basal insulin dose i X X X X X
Time in Auto Mode per week (%) i X X X X X
Laboratory Assessments 
Follicle -stimulating hormone test j X
Serum pregnancy  test X
Urine pregnancy  test X
I8B-MC-ITSM (b) Clinical Protocol Page 12
LY900014Screen
ingLead -In Study Period I Study Period II Safety 
Follow -upEarly 
Termination
Visit 1 2 3a 4 5a6a 7 8a 9a 10 801 ET
Week of Treatment -3 -2 -1 0 * 2 4 * 6 8 10
Visit Window ( ±days) 0 3 3 3 3 3 3 3 3 3 7
Chemistry panel X
Urinaly sis panel X
Hematology X
1.5-Anhydroglucitol X X X X
Hemoglobin A1c X X X X X
Pilot Safety Assessment Specifick
Instruct designated study companion ontheir responsibilities 
throughout the pilot safety assessment and ensure familiarity 
with basic features of the MiniMed 670G pumplX
Ensure patient upload of CareLink Data is completed for 
reviewX
Transfer patient diary data entries related to hypoglycemia, 
unexplained hyperglycemia and unplanned infusion set 
changes into eCRF. Review and discuss all patient diary 
entries.X
I8B-MC-ITSM (b) Clinical Protocol Page 13
LY900014Abbreviations:  AIT =active insulin time ; BG =blood glucose , CGM =continuous glucose monitoring; CR=carb ratio; ECG =electrocardiogram; ET =early 
termination; IP =investigational product; ISF =insulin sensitivity factor; IWRS =interactive web -response sy stem; SMBG =self-monito red blood glucose.
*Denotes 3 -day safety follow -up telepho ne visit after the beginning of each study period .
aTelepho ne visits are indicated by columns shaded a darker shade of gray.  
bPatients must be supine for approximately 5 to 10 minutes before ECG collection and rema in supine but awake during ECG collection.
cVital sign measurements should be determined after patients have been seated quietly for at least 5 minutes in a chair with f eet on the floor.  The arm used for 
blood pressure measurement should be supported at heart level .  
dAll study procedures for a visit should be completed prior to reservoir and infusion set changes during Visits 2, 4, 7, 10 and 801 or ET .
eAt Visit 10 or ET, patients should resume nonstudy insulin. Patients should be instructed to bring their nonstudy insulin with them to the visit in order to 
resume no rmal therapy .
fTraining may be repeated at other visits, as needed .
gPatients should be instructed to perform, at minimum, a 4 -point SMBG profile daily  starting at Visit 2.
hFrom each of the last 3 days prior to screening
iMean from the 1 week prior to Visit 2; m ean f rom the 2 weeks prior to visit for Visits 4, 7, 10,and ET .
jFollicle -stimulating hormone test must be performed at Visit 1 for a p ostmenopausal woman who is between 50 and 54 years of age (inclusive) with an intact 
uterus, not on hormone therapy, and has had at least 6 months of spontaneous amenorrhea .
kPatients participating in the pilot safety assessment will complete all activities listed in the schedule of activities in addition to all pilot -specific activities.
These activities do not need to be completed for patients not participating in the pilot safety assessment .
lDesignated study companions must be present to receive instruction at Visit 4.
I8B-MC-ITSM (b) Clinical Protocol Page 14
LY9000143.Introduction
3.1. Study Rationale
Rapid-acting insulins have been shown to have a more rapid onset of act ion compared with
human insulin; however, the general consensus is that they are not rap id enough to match 
carbohydrate absorption and many  patients are unable to achieve optimal glycemic control.  
An ultra -rapid-acting prandial insulin that would shift the pharmacokinetic (PK) and 
pharmaco dynamic (PD) profiles of insulin to provide an even faster onset of action would better 
match carbohydrate absorption and allow for efficacious dosing immediately prior to meals.  The 
time- action profile o f a rapid -acting insulin could be enhanced through the addition of excipients 
to an exist ing formulation to increase capillary blo od flow and/or enhance vascular permeabilit y.  
An ultra -rapid insulin woul d be useful in the treatment of type 1 di abetes m ellitus(T1D) and 
type 2 di abetes m ellitus (T2D) when delivered by  multiple daily inject ions (MDI) , continuous 
subcutaneous insulin infusio n (CSII), orin closed loop and hybrid closed loop automated insulin 
delivery  systems.
The performance of closed loop and hybrid closed loop insulin delivery systems is limit ed by the 
relatively slow absorpti on of  current rapi d-acting insulin analogs, delaying the onset of action 
and prolonging the duration of act ion.  This is problemat ic during times of rapid glucose 
changes, such as in the postprandial period.  It is hypothesized that r apid glucose changes willbe 
minimized wi th anultra-rapid -acting insulin ina hybrid closed loop system .  Theintegrati on of  
an ultra-rapid insulin with an accelerated PK profile intoa hybrid closed loop algorithm may
increase time pat ients spend in the target glucose range.  
The aim of this study  is to com pare LY900014 and Humalog with respect to the percentage of 
time with glucose values within range (70to180 mg/dL) when both are delivered via CSII by  
the Medtroni c MiniMed 670G System while in Auto Mode as much as possible .  
3.2. Background
There have been many  advances in the treatm ent of T1D in the last 20 y ears; however, reaching 
goals and maintaining glycemic targets remai nchallenging even under intensive insulin therapy 
regimens.  Only  approximately  30% of  insulin
-requi ring patients with diabetes are able to reach 
the goal  hemoglo bin A1c (HbA1c )target of <7% ( Stark Casagrande et al .2013).  Integrated 
insulin pump and continuous glucose monitoring ( CGM )system s may  provide better di abetes 
management, compared with MDI or wi th the pump al one. Some studies suggest that when you 
pair pum p therapy  with the inform ation provi ded by  a glucose sensor, i t may significant ly 
improve HbA1 clevels wit hout increasing the risk of hypoglycemia (Bergenstal  et al . 2010, 
Battelino et al . 2012, Bergenstal et al. 2013)
.
LY900014
LY900014 is comprisedof the act ive ingredient, insulin lispro, and2 enabling excipients 
(treprostinil and citrate) that facilitate rapid absorption of insulin lispro into the blood stream.  
This novel formulat ionresults in earlier gl ucose l owering when compared withHum alog.  Thi s 
I8B-MC-ITSM (b) Clinical Protocol Page 15
LY900014faster glucose -lowering response, as demonstrated by the PKand PDprofiles of LY900014 when 
compared withHumal og, m ore cl osely  mimics the time -action profile of normal endogenous 
insulin secret ion.  Thi s enhanced activit y is expected to provide greater glycemic control as 
dosing relat ive to the start of a meal can be reduced when compared with the timing required for 
the currently available rapid-acting insulin analogs .Dosing closer to the start of a meal will 
allow pat ients to better match the needed insulin dose to the carbohy drate content of their meal .  
Medtronic MiniMed 670G System
TheMedtronic MiniMed 670G system  is intended f or continuous delivery  of basal  insulin and 
administrat ion of insulin bo luses for the m anagement of T1D and for the continuous monitoring 
of interstitial glucose levels . The Medtronic MiniMed 670G Sy stem  consists of the MiniMed 
670G Insulin Pump, the Guar dian Link (3) Transmitter, the Guardian Sensor (3), and the 
CONTOUR NEXT Link 2.4 Glucose Meter. The Guardian Sensor (3) is intended to be used for 
detecting sensor glucose (SG) trends and tracking patterns and to be used by  the MiniMed 670G 
system  to aut omatically adjust basal  insulin levels.  It is indicated for use as an adjunctive device 
to com pliment , but not replace standard blood glucose (BG) testing.  
The MiniMed 670G Sy stem  includes SmartGuard techno logy. There are 2 levels of SmartGuard 
techno logy; Suspend and Auto Mode.
The first level o f SmartGuard techno logy auto matically suspends insulin when the sensor reaches 
a preset l ow limi t (Suspend on low ) or before the low limit is reached (Suspend before low ).
When a Suspend before low occur s, insulin delivery will automat ically resume when the SG
levels recover. The Suspend on low and Suspend before low features are optional features 
available only when the system  is in Manual Mode.
Study  I8B-MC-ITSM (ITSM )will use t he second level of Smar tGuard techno logy, Auto Mode ,
as much as possible .  Auto Mode automat ically calcul ates insulin dose using Guardian Sensor (3) 
data.  Auto Mode is an insulin delivery feature that autom atically  control sbasal insulin delivery 
to regulate glucose level s to a target SG .  The standard target SG setti ng is 120 mg/dL and the 
target can be set temporarily to 150 mg/ dL for exercise and other events .During Auto Mode 
operati on, the user m ust deliv er meal bol uses.The Bolus feature in Auto Mode requires ent ry of
either carb ohydrate or a BG value ,but both may  be entered.  Auto Mode then calculates the 
bolus amount needed to cover the meal or correction. Auto Mode Bolus only allows Normal
boluses.  Square Wave ,Dual Wave ,Easy ,Manual ,Remote ,
and Preset bolus types cannot be 
delivered while in Auto Mode .  
Basic requirements for managing Auto Mode include the following:
Periodic BG testing to calibrate the sensor .  Minimum calibrat ion is every  12 hours .
Use of Auto Mode Bolus functionto cover m eals, an d when thepump recommends a 
bolus.  A BG reading above 150 mg/dL causes Auto Mode to automat ically calculate if a
correcti on bo lus is needed to decrease BG to the 150 mg/dL correcti on target.
Safe Basal  is an automatic funct ion within Auto M ode. Safe Basal allows for time to perform 
additional actions requi red to ensure Auto Mode remains act ive. Safe Basal covers ba sal needs 
I8B-MC-ITSM (b) Clinical Protocol Page 16
LY900014by delivering insulin at a constant rate anddoes not adjust insulin delivery  based on SG values.
Several condit ions can c ause a transit ion into Saf e Basal :
Auto Mode has been at the minimum delivery  limit f or 2.5hours.
Auto Mode has been at the maximum delivery limit for 4 hours.
Auto Mode detects that sensor might be under reading .
An entered BG is 35% or more different th an yourcurrent SG value.
No SG data have been received for more than 5 minutes.
After 90 minutes in Safe Basal, if the condit ion tha t caused the pump to transit ion into Saf e Basal 
has not been reso lved, the pump will enter Manual Mode. The pum p will  indicate the acti ons the 
user needs to take to resume Auto Mode delivery of basal insulin.  
Manual Mode refers to system  functions other than Auto Mode. IfAuto Mode i s not 
funct ioning, the system is in Manual Mode.   
3.3. Benefit/Risk Assessment
Across Phase 1 clinical studi es, LY900014 has consistent ly demo nstrated a faster time -action 
profile than Humalog.  In patients with T1D or T2D treated wi th MDI insulin therapy , 
LY900014 significant ly reduced postprandial glucose excursions co mpared withHumal og when 
both were dosed by syringe at the start of a test meal .  Two studies (I8B -MC-ITRF and 
I8B-MC-ITSC) i n pat ients with T1D have been completed using CSII in an in- patient setting, 
both of which have demonstrated accelerated time action.   LY900014 has been well t olerated in 
both healt hy subjects and patients with diabetes .  
Benefit s to pati ents may  include improved understanding of insulin requirements and 
optimizat ion of pump settings in a hybrid closed loop sy stem  with a faster acting insulin.  
Addit ionally , close m onitoring, frequent vi sits, real -time CGM and self-monitored bl ood gl ucose
(SMBG )all serve to protect subject safet y and minimize risk.  
In Phase 1 studies, the assessment of AEs, hypoglycemic events, local tolerabilit y, vital signs, 
physical examinat ion, electrocardi ogram  (ECG ), anti-insulin lispro antibodies, and clinical 
laboratory  assessments di d not reveal any  specific ri sks o f LY90001 4 bey ond those al ready  
known for Humalog .
Because insulin pump therapy  uses only  rapid -acting insulin, the onset of diabetic ketoacidosis 
(DKA) can occur quickly if insulin delivery is interrupted for a period of time.  D iabetic 
ketoacidosis devel ops when insulin levels are insufficient to meet the body ’s basic metabolic 
requi rements.  Diabet ic ketoacidosis is an acute metabolic co mplication of diabetes characterized 
by hyperglycemia, hyperketonemia, and metabo lic acidosis.  Signs and symptoms may include 
vomiting, abdo minal pain, deep gasping breathing, increased urinat ion, weakness, confusio n, and 
occasi onally  loss of consciousness.  A high BG that is not responding to a correction bo lus via 
insulin pump may indicate an infusio n set occl usion or insulin pu mp probl em.  
I8B-MC-ITSM (b) Clinical Protocol Page 17
LY900014Following the l ead-in period, a 3 -day pilot safet y assessment will be conducted at a single site 
forthe first 10 patients rando mized.  This pilot safety assessment will determine if the control 
algorithm in the Medtroni c 670G pum p can be use d safely  in pat ients receiving LY900014.  
Safety evaluation in this study  will include hypoglycemia, treatm ent-emergent AEs ( TEAEs ), 
serious AEs ( SAEs ), clinical laboratory  assessments, vital signs, pump occl usion alarms, and 
unexplained hyperglycemia leading to unplanned infusio n set changes .  Mo re informat ion about 
the known and expected benefits, risks, SAEs ,and reasonably ant icipated AEs of LY900014 can 
be found in the Invest igator’s Brochure (IB).  
Detailed informat ion about the known and expected benefit s and risks o f Hum alogmay be found 
in the country -specific product labeling ( for exampl e, Pati ent Inform ation Leaflet, Package Insert, 
or Summary  of Product Characterist ics).  
I8B-MC-ITSM (b) Clinical Protocol Page 18
LY9000144.Objectives and Endpoi nts
Table ITSM .2shows the object ives and endpo ints of the study .
Table ITSM .2. Objectives and Endpoints
Objectives Endpoints
Primary
1.To compare LY900014 and Humalog with respect 
to the percentage of time with sensor glucose 
values within range (7 0to180 mg /dL) 1. P ercentage of time with sensor glucose values 
between 70 and 180 mg/dL (both inclusive) ,
during the last 2 weeks of each 4-week treatment 
period
Secondary
2.To compare LY900014 with Humalog with respect 
to the mean sensor glucose2.Mean sensor glucose value (mg/d L), during the 
last 2 weeks of each 4-week treatment period
3.To compare LY900014 and Humalog with respect 
to the percentage of time spent in Auto Mode3.Percentage of time (per week )spent in Auto Mode, 
during the last 2 weeks of each 4-week treatment 
period
4.To compare LY900014 with  Humalog with
respect to the percentage of time with sensor 
glucose values in hypoglycemic glucose ranges4. Percentage of time with sensor glucose values 
<54mg/dLduring the last 2 weeks of each 4-week 
treatment period
5.To compare LY900014 and Humalog with respect 
to the rate of severe hypoglycemic events5.Rate (events/patient/100 years) of severe 
hypoglycemic events during each 4-week 
treatment period
6.To compare LY900014 and Humalog with respect 
to the rate and incidence of documented 
hypoglycem ia6.Rate (events/patient/year) and incidence (percent 
of patients with events) of documented 
hypoglycemic events ,during the last 2 weeks of 
each 4-week treatment period
7.To compare LY900014 and Humalog with
respect to total daily  dose7.Mean total daily bolus insulin dose and mean total 
daily  basalinsulin do se during the last 2 weeks of 
each 4-week treatment period
Tertiary/Exploratory
8.To compare the safety of LY900014 and Humalog 8.Adverse events and vital signs
9.To compare LY900014 and Humalog with respect 
to the percentage of time with sensor glucose 
values within range (7 0and 140 mg /dL) 9. P ercentage of time with sensor glucose values 
between 70 and 1
40 mg/dL (both inclusive) ,
during the last 2 weeks of each 4-week treatment 
period
10.To compare LY900014 and Humalog with respect 
to the rate and incidence of unplanned infusion set 
changes10.Rate (events/patient/30 days) and incidence of 
unplanned infusion set changes by reason ( Pump 
occlusion alarm, unexplained high BG, Infusion 
site reaction [pain, redness or swelling at inf usion 
site], or Infusion set problem [infusion set kinked, 
pulled out, leaking, reservoir empty, etc ]), during 
the 4-week treatment period
11.To compare LY900014 and Humalog withrespect 
to the percentage of time with sensor glucose 
values in hyperglycemic glucose ranges11. P ercentage of time with sensor glucose values 
>180mg/dL and >250 mg/dL , during the last 
2weeks of each 4-week treatment period
I8B-MC-ITSM (b) Clinical Protocol Page 19
LY900014Objectives Endpoints
12.To compare LY900014 and Humalog with respect 
to the 1 -hour postprandial sensor glucose 
excursions12.Mean 1- hour postprandial sensor glucose 
excursions ( mean sensor glucose measured 1 hour 
after the start of the meal minus mean sensor
glucose at the start of meal )after b reakfast , during 
the last 2 weeks of each 4 -week treatment period
13.To compare LY900014 and Humalog with respect 
to the within -patient sensor glucose variability 13. Coefficient of variation (CV) (standard 
deviation/mean) of sensor glucose values , during 
the last 2 weeks of each 4-week treatment period
14.To evaluate HbA1c of LY900014 and Humalog 14.Summary statistics of actual and change of HbA1c 
during each 4 week treatment period
15.To evaluate 1,5-AG of LY900014 and Humalog 15.Summary statistics of actual and change of1,5-AG
during each 4-week treatment period
16.To compare LY900014 and insulin lispro with 
respect to the factors affecting dosing in pumps16.Actual and change from baseline in factors 
affecting dosing in pump (breakfast CR, AIT , 
breakfast ISF ), during the 4 -week treatment period
Abbreviations : 1,5 AG =1,5 Anhydroglucitol ;AIT =active insulin time ; BG=blood glucose ; CR =carb ratio ; 
ISF=insulin sensitivity factor .
I8B-MC-ITSM (b) Clinical Protocol Page 20
LY9000145.Study  Design
5.1. Overall Design
This study  is aprospective, rando mized, double -blind, outpatient, 2-treatm ent , crossover, 
active -controlled study  conducted in pati ents wi th T1D currently  using an external CSII pump.  
In the 2treatm ent period s, LY900014 and Humal ogwill be delivered via the Medtronic 
MiniMed 670G system with SmartGuard™ technology using AutoMode.  In this study , pati ents 
will be required to use the Auto Mode insulin delivery  functionas much as possible .  
The study  is desi gned to com pare LY900014 and Hum alogwith respect to the durati on of  time 
glucose values are within range (70to180 m g/dL) .  The study  includes a 1- week screening 
period and a 2 -week lead -in peri od followed by  a 2-period crossover, each period consisting o f 
4weeks of treatm ent, and a 2-week post -treatm ent safet y follow
-up.  
Following the l ead-in period, a 3 -day pilot safet y assessment will be conducted at a single site in 
the first 10 patients rando mized.  This pilot safety assessment will determine if the control 
algorithm in the Medtroni c 670G pum p can be used safely  in pat ients receiving LY900014.  
Patients randomized into the pilot safet y assessment will remain blind ed to treatm ent and 
undergo study  procedures in the Schedule of Act ivities with addi tions denoted at the bottom.  
These pat ients will be required to have addit ional safet y oversight in the form of a designated 
study  com panion (spouse, a partner, or someone living in the househo ld)who is required to be 
with the pati ent overnight for the first 3 day s of the study .  The invest igative site will check in 
with the pati ent at Day  1 via a tel ephone call.  During the Visit 5 telephone call, the invest igator 
will re view patient data and determine if the pat ient can continue study  treatm ent.  More details 
on the pilot safet y assessment are described in Sectio n 9.4.6.1 .  
The pilot patients will contribute to the total number of patients randomized.  No additional 
patients will  be randomized unt il after a blinded review of the pilot patients’ safet y data occurs.  
Within 1 week of all 10 pat ients com pleting the 3 -day pilot safet y assessment , the invest igator 
will review the data in consultat ion with the Sponsor .  After complet ion of the pilot safet y 
assessment, t he invest igator and the Sponsor will determine if random ization can continue .  
Study  governance considerations are described in detail in Appendix 3 .
Figure ITSM .
1illustrates the study  design.
I8B-MC-ITSM (b) Clinical Protocol Page 21
LY900014Figure ITSM .1. Illustration of study design for Clinical Protocol I8B-MC-ITSM .

I8B-MC-ITSM (b) Clinical Protocol Page 22
LY9000145.2. Number of Participants
Approximately  50participants will be screened to achieve 42randomized for atotal of 
approximately  36patients to complete the study .  Pilot pati ents will  contribute to the overall 
number of participants.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on 2)for the last patient.
5.4. Scientific Rationa le for Study Design
A pilot safet y assessment was added to the study  design after consultation wit h FDA in 
December 2018.  The purpose of the pilot will be to assess the safet y of LY900014 when 
administered via the Medtronic 670 Gpump before enrolling a la rge number of pati ents.  
A crossover design was chosen for this study  to reduce variabilit y and increase the power as each 
patient serves as his or her own control.   
At the crossover point, patients are required to change their reservo ir and infusion set .The 
investigator will reset the patient’s pump to randomizat ion settings . Treatment comparisons will 
use the data collected during the last 2 weeks of each period .  This will minimize carry over effect 
on the primary  analysis o f efficacy, safet y, and exploratory  outcom es.  
5.5. Justification for Dose
The basal and bo lus delivery  of insulin in this study willbe determined based on the indi vidual  
needs of each patient.  LY900014 hasthe same insulin lispro concentration (100 U/mL) as that 
of commercially  available Humalog.  In Phase 3 clinical studies, LY900014 and Humalog were 
subst ituted unit for unit.  Humalog has been in the market for over 20 years with widespread use 
worldwide and has extensive efficacy and safety data .  The addit ion of treprosti nil to the insulin 
lispro form ulation does not m odify  the physical , chemical, or bi ological integri ty of insulin 
lispro.  The total serum insulin lispro exposure (area under the concentration curve fro m 0-to 
5-hour post dose) are similar between LY900014 and Humalog in T1D CSII.  In addition, the 
total glucodynamic act ivity measure din euglycemic clamp studies w assimilar between 
LY900014 and Humalog .
I8B-MC-ITSM (b) Clinical Protocol Page 23
LY9000146.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.   There are addit ional criteria for pati ents who 
participate in the pilot safet y assessment of the study .
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of thefollowing cri teria at 
screening :
Type o f Patient a nd Disease Characteristics
[1] Men or women d iagnosed (clinically ) with T1D for at least 1 year prior to screening and 
continuously using insulin for at least 1 y ear
Patient Characteristics
[2] Are at l east 18 y ears of age 
[3] Male patients:
a)No m ale contraception required.
[4] Female pat ients: 
a)Women not of childbearing potential may participate and include those who 
are:
i)infertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal  ligation), congenital ano maly such as Mullerian 
agenesis
Or
ii)postm enopausal –defined as eit her
(1)a wom an 50 to 54 y ears of age (inclusive) with an intact uterus, not 
on hormone therapy  who has had ei ther
(a)cessat ion of menses for at least 1 y ear
Or
(b)at least 6 m onths of spontaneous amenorrhea with a 
follicle -stimulat ing horm one >40 m IU/mL
Or
(2)a wom an aged 55 y ears or ol der not on hormone therapy , who has 
had at least 6 months of spontaneous amenorrhea
Or
I8B-MC-ITSM (b) Clinical Protocol Page 24
LY900014(3)a wom an of at l east 55 y ears of age wit h a di agnosis of menopause 
prior to starting hormone replacement therapy
b)Women of childbearing potential who are participating:
i)cannot be pregnant or intend to become pregnant
ii)cannot be breastfeeding (including the use of a breast pump) 
iii)must remain abstinent or use 1 hig hly effect ive method of contraception 
or a combinat ion of 2 effect ive methods of contraception for the ent irety 
of the study (Appendix 5 )
iv)test negative for pregnancy  at the time of screening (Visit 1); note:  a 
urine pregnancy test is conducted at Visit 4
[5] Have been using CSII therapy  for a minimum o f 6 months prior to screenin g.  
Interrupti on of  CSII is allowed once during the 6 mo nths prior to screening for up 
to 14 consecut ive days, such as during a hospitalization, a pump malfunct ion, or 
a “pump ho liday”
[6] Are current ly treated with the same rapid -acting analog insulin (insuli n lispro 
U-100 or insulin aspart) via CSII for at least the last 30 day s prior to screening
[7] Have HbA1c values ≥6.0and ≤8.0%, as determined by  the central  laboratory  at 
screening (Visit 1)
[8] Have a body  mass index of ≤35 kg/m 2at screening (Visit 1)
[9] Are prof icient, in the opinion o f the invest igator, in carbohydrate counting
[10] Are willing to adhere to an infusio n set and reservoir change interval o fevery  
3days.
[11] Must be using a Medtronic MiniMed 670G insulin pump 
a)For at l east 90 days prior to screening in Aut o Mode 
b)In Auto Mode at least an average of 70% of the time per week during the 
last 4 weeks prior to screening 
c)With a Medtronic Guardian (3) sensor at least an average of 75 % of  the 
time per week during the last 4 weeks prior to screening
d)And willing to stay on the 670G pump throughout the study
e)And willing to maintain the bo lus delivery speed used at screening for the 
durati on of  the study
f)And willing to avoid use of all products containing acetaminophen while 
using the Medtronic Guardian (3) sensor
g)And willing to use study -provi ded Medtroni c MiniMed insulin pump 
reservo irs and Mi o infusio n sets
I8B-MC-ITSM (b) Clinical Protocol Page 25
LY900014h)And willing to use the Auto Mode Bolus feature to deliver bo luses to cover 
meals and correcti ons, and whenever the pump recommends a bolus   
[12] Are willing to perfor m BG testing using the ir personal Contour Next Link 2.4
meter 4times each day premeal and bedtime , including for sensor calibrat ions,
and to confirm hypoglycemia and unexplained hyperglycemia, and willing to 
respond to periodic requests fro m the pum p for BG readings without the need for 
calibrat ion
[13] Have access to a telephone, or alternative means for close monitoring and 
communicat ions
[14] Have refrigerat ion in the ho me or have ready access to refrigeration for storage of 
insulin
Informed Consent
[15] Have given wr itten inform ed consent to participate in this study  in accordance 
with local regulat ions
6.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at
screening or at other visit s, only when indicated :
Medical Conditions
[16] Have hypoglycemia unawareness as judged by the investigator
[17] Have had more than 1 episode of severe hypoglycemia (defined as requiring 
assistance due to neurologically disabling hypoglycemia) within 6 months prior 
to screening
[18] Have had anyemergency  depar tment visit or hospitalizat ion due to poor BG 
control  (hyperglycemia or DKA) within 6 mo nths prior to screening
[19] Have a t otal daily  insulin dose > 100 uni ts, as determined by the average total 
daily  insulin dose over the 3 day s prior to screening .  
[20] Have significant lipohypertrophy , lipoatrophy , or scars wi thin the subcutaneous 
tissue in areas o f infusio n, in the opinio n of the investigator
[21] Have a history  of abscess at an infusio n site wi thin the l ast 90 day s prior to 
screening
[22] Have visio n loss or hearing loss that does not allo w recogni tion of  pump screens, 
alerts, and al arms
[23] Have presence of clinically significant gastrointestinal disease (for example, 
clinically act ive gastroparesis ass ociated wi th wide gl ucose fluctuati ons; in the 
investigat or’s opinion) or gastric bypass
I8B-MC-ITSM (b) Clinical Protocol Page 26
LY900014[24] Have any other condit ion (including known drug or alcoho l abuse or psy chiatric 
disorder including eat ing disorder) that precludes the pat ient from following and 
completing the protocol
[25] Have cardio vascular disease, within the last 6 months prior to screening, defined 
as stroke, decompensated heart failure New York Heart Associat ion Class III or 
IV, (CCNYHA 1994), myocardial  infarcti on, unstable angina pectoris, 
percutaneous transluminal coronary  angi oplast y or coronary  arteri al bypass graft .  
[26] Renal: 
a)History  of renal  transplantati on
b)Current ly receiving renal dialysis 
c)Serum  creatinine >2.0 mg/dL (177 μmo l/L) at screening (Visit 1) as 
measured by the central laborat ory
[27] Hepati c:
a)Have obvious clinical signs or symptoms o f liver disease (for example, 
acute or chronic hepat itis, or cirrhosis), or elevated liver enzyme 
measurements as indicated below at screening (Visit 1)
b)Total  bilirubin leve l (TBL) ≥2X the upper limit o f norm al(ULN) (wi th the
exception of Gilbert’s disease) as defined by the central laboratory  
Or
c)Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3X
ULN as defined by  the central  laboratory
[28] Malignancy: have act ive or un treated m alignan cy, have been in remissio n from 
clinically significant malignancy (other than basal cell or squamous cell skin 
cancer) for less than 5 y ears, or are at an increased risk for developing cancer or a 
recurrence of cancer in the opinio n of the invest igator
[29] Have any hypersensit ivity or allergy  to any  of the insulins or excipients used in 
this trial
[30] Hem atologic: have had a blood transfusio n or severe blood loss within 90 days 
prior to screening or have known hemoglo binopathy, anemias, or any  other trai ts 
known t o interfere wit h measurement of HbA1c
Prior/Concomitant Therapy
[31] Have used insulin human inhalat ion powder (Afrezza ®) within 2 weeks prior to 
screening
[32] Are receiving any oral or injectable medicat ion intended for the treatment of 
diabetes other than rapid-a cting analog insulin via CSII in the 30 days prior to 
screening. Occasional pen or sy ringe inject ion of insulin is allowed in the event 
of pum p malfunct ion, unexplained hyperglycemia not responsive to pump 
correcti on bo lus, etc.
I8B-MC-ITSM (b) Clinical Protocol Page 27
LY900014[33] Glucocorti coid therapy: ar e receiving chronic (last ing longer than 7 consecut ive 
days) systemic glucocortico id therapy (including intravenous, IM, subcutaneous, 
and oral), but excluding topical, intraocular, intranasal, intra-articular, and 
inhaled preparations), or have received s uch therapy  within 2 weeks immediately  
prior to screening with the exception o f replacement therapy  for adrenal  
insufficiency
Prior/Concurrent Clinical Trial Experience
[34] Are current ly enrolled in any other clinical study  involving an invest igational 
product (IP) or any  other ty pe of  medical  research judged not to be scient ifically 
or medically com patible with this study
[35] Have participated, within the last 30 days in a clinical study involving an IP.  If 
the previous IPhas a long half -life, 3 months or 5 half -lives (whichever is longer) 
shoul d have passed;
Other Exclusions
[36] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted
[37] Are Lilly  empl oyeesor representatives (including emplo yees, tem porary  contract 
workers, or designees responsible for the conduct of the study )
[38] Have an irregular sleep/wake cycle (for example, patients who sleep during the
day and work during the night)
[39] Are unable and/or unwilling to provide informed consent, to make themselves 
available for the duration of the study , or to abi de by  study  procedures
Pilot Patients
[40] All patients participat ing in the pilot safet y assessment must have an adu lt (≥18 y ears ol d) 
designated study  com panion that will  reside at the same location overnight during the pilot 
andagree to sl eep in the same room  with the pati ent, sleep within hearing distance of the 
CGM and pump alarms, be willing to awaken at least onc e between 2:00 AMand 4:00 
AMto assist the pa tient in checking BG,and be willing to assist the patient in 
troubleshooting an alarm if one should occur during the night. The designated study  
companion must agree to these responsibilit ies for the 3-day durat ion of the pilot safet y 
assessment.
I8B-MC-ITSM (b) Clinical Protocol Page 28
LY9000146.3. Lifestyle Restrictions
During the study , pati ents m ust avo id:
donat ingblood or bl ood products 
major changes in diet or exercise 
all medicat ions that contain acetaminophen .
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
rescreened , with the except ion of individuals who screen fail due to ; 
Inclusio n
[11] Must be using a Medtronic MiniMed 670G insulin pump 
b)In Auto Mode at least an average of 70% of the time per week 
during the last 4 weeks prior to screening 
c)With a Medtronic Guardian (3) sensor at least an average of 75% 
of the time per week during the last 4 weeks prior to screening
Exclusio n
[19] Have a total  daily  insulin dose > 100 units, as determined by the average 
total daily insulin dose over the 3 days prior to screening.  
Or Com binat ion of any above
If an individual screen fails due to one of the reasons listed, the individual may be rescreened 
once, no sooner than 2 weeks after the ini tial screening. Patients who rescreen are not eligible to 
participate in the pilot safet y assessment .  
Retests, outside of rescreening, are not allowed, except for cases when results are not available 
from the original  sample .  It is expect ed that any  lab orprocedure performed in the init ial 
screening berepeated for rescreened patients .  
I8B-MC-ITSM (b) Clinical Protocol Page 29
LY9000147.Treatment s
7.1. Treatments Administered
This study  involves a comparison of LY900014 and Humalog delivered via CSII using the 
Medtroni c MiniMed 670G insulin pump .  Throughout the study , patients will use their personal 
Medtroni c MiniMed 670G pum pand the study  provided, Guardi an Link (3) Transmitter, 
Guardi an Sensor (3) glucose sensors , and Contour Next Link 2.4 Blood Glucose Meter .  Patients 
will be required to use the reservo irs and infusio n sets provi ded by the invest igative site.  
Table ITSM .3shows the treatment regimens.
All patients not currently using insulin lispro in their pumps will begin using Humal ogat the 
beginning of the 2 -week l ead-in period.  Following the lead -in peri od, 10 patients will be 
rando mized in a double -blind manner to 1 of the 2 treatment sequences in a 1:1 ratio and enter a 
pilot safet y assessment.   After com pleteti on of  the pil ot safet y assessment , the invest igator along 
with Lilly  will determine if randomizat ion can continue.   
Table ITSM .3. Treatment Regimens
Regimen Dose Strength Dose Administration Route of Administration Timing of Dose
LY900014 100 U/mL Individualized dosing CSII Mealtime bolus 0-2 min 
prior to start of meal;
correction bolus as needed;
and basal infusion ; 
Humalog 100 U/mL Individualized dosing CSII Mealtime bolus 0-2 min 
prior to start of meal; 
correction bolus as needed; 
and basal infusion 
Abbreviations:  CSII =continuous subcutaneous insulin infusion .
The invest igator or his or her designee is responsible for the following:
Explaining the correct use of IPto the patient 
Explaining storage requirements for IP to the patient
Maintaining accurate records of IPdispensing and collect ion
At the end of the study ,returning all used and unused IPto Lilly, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law
7.1.1. Packaging and Labeling
Clinical trial materials will be labeled as IP as appropriate, and according to regula tory 
requi rements.   Study  insulins (LY900014 and Humalog ) will  be supplied by  Lilly  or its 
representative, in accordance with current good manufacturing pract ices and will be supplied 
with lot numbers.
The blinded vials will contain a concentration of 100 U/mL in 10 -mL vials o f either LY900014 
or Humalog .  
I8B-MC-ITSM (b) Clinical Protocol Page 30
LY900014During the l ead-in period, Hum alog100 U/m L will  be provi ded in open -label 10 -mL vials.
7.1.2. Insulin Pumps
Patients will  use thei r personal  Medtroni cMiniMed 670G pump , the study  provi dedContour 
Next Link 2. 4 meter, and Medtroni c Guardian Sensor (3) Transmitter and sensors throughout the 
study .All pat ients will be required to use MiniMed reservo irs and Mio infusion sets with 6 -mm 
or 9-mm cannula and 32-inch tubing.  If the infusion set cannula length is changed during the 
study , itshoul d be docum ented.  The Mio infusio n set was chosen because of its all -in-one 
design that combines the infusio n set wi th the inserter device.  
7.1.2.1. Pump Bolus Delivery Speed
Patients will  be allowed to use Stan dard (1.5 U/min) or Quick (15 U/min) pump bolus delivery  
speed.  Patients must maintain the same speed throughout the ent ire study .
7.1.2.2. Pump Bolus Delivery Time
Patients will  deliver bol us doses to cover carbohydrate intake at 0 to 2 minutes prior to 
consumpti on.
7.1.2.3. Pump Alerts
Patients shoul duse the Auto Mode feature of their MiniMed 670G pump as much as possible 
throughout the trial, including u se of the Auto Mode Bolus feature to deliver bo luses to cover 
meals, and when ever the pum p recommends a bo lus.  
Factory  set Auto Mode Exit High and Low Sensor Glucose Alerts cannot be silenced and are 
always enabled when the pump is in Auto Mode.
The pum p will exi t Auto Mode based on a set SGthresho ld:
300 m g/dL or hi gher for 1 hour
250 m g/dL or hi gher for 3hours
50 m g/dL or lower for any  period of  time .  
Factory  set Low Alert cannot be silenced and is always enabled, whether the pump is in Auto 
Mode or Manual Mode.
In addit ion, study  site programmed Sensor Gl ucose Alerts will be standardized for all pat ients 
throughout the study. High Alerts will be set to occur when SGreaches >180 mg/dL and Low 
Alerts will be set to occur when SGreaches <70 mg/dL.
7.2. Method of Treatment Assignment
Patients who meet all criteria for enrollment and complete the lead -in peri od will be rando mized 
to double -blind treatment at Visit 4.  Assignment to treatment sequences will be determined by a 
computer -generated random sequence using an interactive web- response system (IWRS).  
Patients will be randomized to 1 of the 2treatm ent sequenc es in a 1:1 ratio:
Sequence A:  LY900014 Humalog
Sequence B: Humalog    
LY900014
I8B-MC-ITSM (b) Clinical Protocol Page 31
LY900014Stratificat ion will be by HbA1c stratum  (≤7.0%,>7.0% at Visit 1) and percentage of time with 
SGvalues from 70to180mg/dL over the 2 weeks prior to randomizat ion (≤75%, > 75%).  
Patients will  begin using a new reservo ir and infusio n set prior to leaving the invest igative site at 
Visits 2, 4, 7 and 10.  Patients will change the pump reservo ir and infusio n set every  3 days
unless a change is required due to a failure of the infusio n set.
The IWRS will be used to assign all study  treatm entduring the study, including Humal ogduring 
the lead -in period.  The IWRS will be used to assign vials containing double -blind IP to each 
patient randomized to the treatm ent sequence s.  
Site personnel will confirm that they  have 
located the correct vi als by  entering a confirmat ion number found on the vials into the IWRS.
7.3. Blinding
This is a double -blind study  in which the treatments, LY900014 and Hum alog, will have basal 
and bo lus doses delivered via CSII.  Invest igators, patients, and study  site personnel will be 
blinded to assigned dosing regimens throughout the study .  
To preserve the blinding of the study , the Lilly study  team  will remain blinded throughout the 
study; only a minimum number of Lilly personnel will see the rando mizat ion table and treatment 
assignments before the study  is com plete.  
Emergency  unblinding for AEs m ay be perform ed through the IWRS.  This option may  be used 
ONLY if the pat ient’s well -being requires knowledge of  the patient’s treatment assignment.  
Unblinding events are recorded and reported by  the IWRS.  
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient 
must be discont inued fro m the study .  
In case of an emerge ncy, the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted.  Patient safet y must always be the first 
consideration in making such a determinat ion.  If the invest igator decides that unbli nding is 
warranted, the invest igator should make every effo rt to con tact the Lilly clinical research 
physician (CRP)/clinical research scient ist (CRS) prior to unblinding a patient’s treatment 
assignment unless this could delay emergency treatment of the p atient.  If a pati ent’s treatm ent 
assignment is unblinded, Lilly must be notified immediately.
7.4. Dosage Modification
See Secti on 7.1.2
7.5. Preparation/Han dling/Storage/Accountability
The invest igator or his or her designee is responsible for the following:
Confirming appropri ate tem perature condi tions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and
resolved before use of the study  treatm ent.
I8B-MC-ITSM (b) Clinical Protocol Page 32
LY900014Ensuring that only participants enrolled in the study may receive IPand only 
authori zed si te staff may  supply  or administer study  treatm ent. 
Ensuring a ll study  treatm ents m ust be stored in a secure, environme ntally 
controlled, and monitored (manual or automated) area in accordance with the 
labeled storage condit ions with access limited to th e invest igator and authorized 
site staff .
oAll insulin products must be stored at the investigative site under refrigerate d 
condi tions (between 2°C and 8°C) in a locked and secure place.  Insulin must not 
be frozen.
oVials o f insulin not currently in use should be refrigerated un til ready  to use.  
In-use insulins should be maintained at room temperature, and refrigerated 
materi al should be warmed to near room temperature before infusio n.  In -use 
insulin must not be used after 28 days.
The invest igator, institution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as receipt, reconciliat ion and final disposit ion records).
7.6. Treatment Compliance
The invest igator or designee will assess compliance of the patient at each visit, based on a review 
of the patient ’sCareLink repor ts, glycemic control, adherence to the visit and treatm ent schedule, 
and co mpletion of the pati ent’s study  diary.  Pati ents who are deemed nonco mpliant will receive 
additional diabetes educati on and training, as required, and the importance of compliance w ith 
the protocol will be reinforced.  Patient s who, in the opinion o f the invest igator, are deemed 
consistent ly noncom pliant m ay be discontinued from the study .  No specific study  data will be 
collected to analyze treatment compliance.
7.7. Concomitant Therapy
The fo llowing concomitant medicat ions 
are NOT allowed at any t imeduring the study; 
oAfrezza® (inhaled insulin)
oAny noninsulin diabetes treatment therapy
oAcetaminophen
oSystemic glucocorti costeroi d 
IV, IM, SC, oral
except in the case of replacement therapy  for adrenal  
insufficiency
ARE allowed for a maximum  of 48 hours during each treatment period
oBasal insulin
I8B-MC-ITSM (b) Clinical Protocol Page 33
LY900014oRegular human insulin or a nonstudy  rapid-actinganalog insulin
ARE allo wed at any  time
oTopical, inhaled, intraocul ar, intra-articular, or intranasal  steroi d 
preparati ons
7.8. Treatment after the End of the Study
7.8.1. Treatment after Study Completion
LY900014 will not be made available to patients after conclusion o f the study .  Rapi d-acting 
insulin analogs are available in all countries for use as prandial/pump insulin.  
7.8.2. Special Treatment Considerations
After di scontinuat ion of IP at the end of the treatment period or earlier, randomized patients 
shoul d start a nonstudy  rapid -acting analog insulin via CSII.  
Invest igators should provide pat ients with appropri ate gui dance for glucose monitoring and 
insulin dose adjust ment throughout the fo llow-up peri od to m aintain glycemic control.  
I8B-MC-ITSM (b) Clinical Protocol Page 34
LY9000148.Discontinuation Criteria
8.1. Discontinuation fr om Study Treatment
Patients who need to di scont inue from study  treatment will also be discont inued fro m the Study .  
Please refer to Section 8.2.
8.1.1. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ifiesa pati entwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study .  If the invest igator 
and the spons or CRP/CRS agree that it is medically  appropri ate to continue, the invest igator 
must obtain documented approval fro m the sponsor CRP /CRS to allow the inadvertent ly enro lled 
patientto continue in the study  with IP. Safet y follow-up is as outlined in Sect ion2(Schedule of 
Activities), Section 9.2(Adverse Events), and Sectio n9.4(Safet y) of the protocol.
8.2. Discontinuation from the Study
Patients will  be discont inued in the fo llowing ci rcumstances:
The invest igator may decide that the patient should stop IP.  If this decisio n is 
made because of an AE, SAE, or a clinically significant laboratory  value, the 
study  drug i s discont inued for that patient and appropriate measures are t o be 
taken.  Lilly or its designee is to be al erted immediately
The patient may  decide to stop IP 
The patient beco mes pregnant
If an invest igator, study site personnel performing assessments, or patient is 
unblinded, the patient must discont inue IP  
Frequent use of prohibited conco mitant m edication
Use of pump other than the Medtroni c MiniMed 670G.
The patient has not used IP for more than 3consecutive days 
Enrollment in any other clinical study  involving an IP or enrollment in any 
other ty pe of medical research judged not to be scient ifically or m edically 
compatible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , 
or other reasons consistent with applicable laws, regulat ions, and good clinical 
practi ce
A pat ient experiences any episode of clinically  diagnosed Di abetic Ketoacidosis 
(DKA) during the study
oDKA is defined as an acute metabo lic co mplication of diabetes characterized 
by hyperglycemia, hyperketonemia, and metabo lic acidosis. Hyperglycemia 
causes an osmotic diuresis with significa nt fluid and electrolyte loss. DKA 
causes nausea, vo miting, and abdo minal pain and can progress to cerebral 
I8B-MC-ITSM (b) Clinical Protocol Page 35
LY900014edem a, com a, and death. DKA is diagnosed by detection of hyperketonemia 
and anio n gap m etabo lic acidosis in the presence of hyperglycemia. 
Treatm ent invo lves volume expansio n, insulin replacement, and prevent ion of 
hypokal emia
A pat ient parti cipat ing in the pilot experiences any episode of severe hypoglycemia 
during the first 3 days of the pilot safety assessment
A pat ient experiences >1 episode of severe hypoglycemia during the study
A pilot patient’s designated study  com panion does not comply wit hassigned 
responsibilit ies or is no longer available during pilot and transfer of study  com panion 
responsibilit ies is not possible for remainder of pilot safet y assessment
Invest igator decisio n
othe invest igator decides that the patient should be discontinued from 
the study
oif the pat ient, for any  reason, requi res treatm ent with another 
therapeuti c agent that has been demo nstrated to be effect ive for 
treatm ent of the study  indicat ion, discont inuat ion from  the study  
occurs pri or to introducti on of  the new agent
Subject decisio n
othe patient requests to be withdrawn fro m the study
Discontinuation due to a hepatic event or liver test abnormality:   patients
who a re discontinued due to a hepatic event or liver test abnormalit y shoul d 
have addit ional hepatic safety  data collected via electroni c case report form
(eCRF ).
Discontinuati on for abnormal  liver tests should be considered by the 
investigator when a patient meets one of the fo llowing condit ions after 
consultation wit h the Lilly -designated m edical m onitor:
oALT or AST >8X ULN
oALT or AST >5X ULN for more than 2 weeks
oALT or AST >3X ULN and TBL >2X ULN or internat ional 
norm alized rati o >1.5 
oALT or AST >3X ULN with the appearance of fat igue, nausea, 
vomiting, right upper- quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
oalkaline phosphatase (ALP) >3X ULN
oALP >2.5X ULN and TBL >2X ULN
oALP >2.5X ULN wi th the appearance of fatigue, nausea, vomit ing, 
right quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
I8B-MC-ITSM (b) Clinical Protocol Page 36
LY900014Patients di scont inuing fro m the study  prem aturely for any  reason shoul d com plete AE and other 
safet y follow-up per Secti on 2(Schedule of Activit ies), Section 9.2(Adverse Ev ents), and 
Secti on 9.4(Safet y) of this protocol , with the excepti on of  those who di scontinue during the 
lead-in period will not need to have laboratory  tests drawn.
8.3. Lost to Follow -up
A patientwillbe considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.  Due diligence efforts should be documented in eCRF.  
Lilly personnel will not be invo lved in any attempts to collect vital status informat ion.
I8B-MC-ITSM (b) Clinical Protocol Page 37
LY9000149.Study  Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, wi th the study  procedures and their timing (including 
tolerance limit s for timing).
Appendix 2 lists the l aboratory  tests that will be performed for this study .
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed wi thin 60 days o f recei pt of  confi rmed test resul ts.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.   
9.1. Efficacy Assessments
9.1.1. Primary Assessments
Percentage o ftime in range (%) of target SGvalues collected.
9.1.2. Secondary Assessments
Percentage of time in range (%) of hypoglycemic SGvalues collected 
Percentage of time (%) per week spent in Auto Mode
Mean SGvalue
Rate and incidence of hypo glycemia events
Mean total daily  basal insulin dose
Mean total daily  bolus insulin dose
9.1.3. Appropriateness of Assessments
All assessments included in this study  are generally  regarded as reliable and accurate with 
respect to diabetes .
9.1.4. Study Procedures
9.1.4.1. Continuous Glucose Monitoring
The Medtronic MiniMed 670G Sy stem  consists of the following devices: 
MiniMed 670G Insulin Pump, 
Guardi an Link (3) Transm itter, 
Guardi an Sensor (3),
CONTOUR NEXT Link 2.4 Glucose Meter.  
Patients will  use all of the System  com ponents throughout the trial.  All therapy adjust ments 
shoul d be based on measurements obtained using the CONTOUR NEXT Link 2.4 Glucose Meter 
and not on values provided by the Guardian Sensor (3). The Guardian Sensor (3) is intended for 
use with the Medtroni c MiniMed 670G system to continuously mo nitor glucose l evels in patients
withdiabetes. It is intended to provide an indication of when a finger stick may be requi red, for 
detecti ng trends and t racking patterns , and to be used by  the Medtroni c MiniMed 670G system  to 
I8B - MC- IT SM  (b )C l in ica l  P ro toco l Page  38
LY900014au tom a t i c a l l y  a d j u s t  b a s a l  i n s u l i n  l e v e l s .   T h e  Gu a rd ian  S en so r  (3 )  i s  ind i c a t ed  fo r  7  d ay s  o f  
c o n t i n u o u s  u s e .T h e  s e n s o r  m u s t  b e  c a l i b r a t e da t  a  m i n im um  o f  ev e ry  12  hou r s ,  bu t  i t  i s
r e c omm e n d e d  t h a t  th es en so r  i s  c a l i b r a t e d  3o r4t im e s  e a ch  d ay .
P a t ien t s  m u s t  u s e  SMBG  v a l u e s  t a k e n  o n l y  f r om  f i n g e r - s t i c k s  f o r  c a l i b r a t i o n s .   D o  n o t  u s e  
a l t e r n a t i v e  BG  s i t e  t e s t i n g  ( f o r e a rm ,  p a lm ,  e t c . )  f o r  s e n s o r  c a l i b r a t i o n .
A v oi d  p rodu c t s - c o n ta i n i n g  a c e t am i n o p h e n  w h i l e  u s i n g  t h e  M e d t r o n i c  M i n iM e d  6 7 0G  s y s t em .   
T ak ing  me d i c a t i o n s  w i th  a c e t am inoph en ,  in c lud ing ,  bu t  no t  l im i t ed  to  Ty l eno l ®,f e v e r  r e d u c e r s ,  
o r  co l d  m ed i c in e ,  wh i l e  w e a r ing  th e  s en so r  m ay  f a l s e ly  r a i s e  SGr e a d i n g s .
9 .1 .4 .3 .In f us ion  Se t  Changes
P a t ien t s  shou l d  c h a n g e  t h e i r  i n f u s i on  s e t  a n d  r e s e r v oi r  e v e r y  3  d a y s .
T h e  p a t i en t ’ s  s tudy  d i a ry w i l l b e  u s ed  to  co l l e c t  u n p l a n n e d  i n f u s i o n  s e t  c h a n g e s ,  i n c l u d i n g  d a t e  
a n d  t im e  o f  c h a n g ea n d  t h ep r im a ry  r e a son  fo r  u n p l a n n e dc h a n g e .
 Pump  o c c l u s i on  a l a rm ,
 Un e x p l a i n e d  h i g h  BG,  
 I n f u s i o n  s i t e  r e a c t i o n  ( p a i n ,  r e d n e s s  o r  sw e l l i n g  a t  i n f u s i on  s i t e ) ,  o r  
CC I
I n f u s i o n  s e t  p r o b l em  ( i n fu s i on  s e t  k i n k e d ,  p u l l e d  o u t ,  l e a k i n g ,  r e s e r v oi r  em p ty , e t c . ) .   
U n e x p l a i n e d  h y p e r g l y c em i a  i s  d e f i n e d  a s  hi g h  BG> 3 0 0m g / dL  th a t  c anno t  b ee x p l a i n e d  b y  a  
m i s s ed  p r io r  bo lu s ,  d i e t a ry i n d i s c r e ti o n ,  r e b o u n d  o r  t r e a tm e n t  o f  h y p o g l y c em i a ,  a  p um p  f a i l u r e ,  
a n  em p t y  pum p  r e s e rv o i r ,  a n  i n f u s i o n  s e t  c om p l i c a t i o n  ( f o r  e x am p l e ,  k i n k e d ,  c am e  o u t ,  l e a k i n g ) ,  
o r  a n  i n f u s i on  s i t e  c om p l i c a ti o n  ( f o r  e x am p l e ,  p a i n ,  r e d n e s s ).
I n v e s t i g a t o r s  w i l l  r e v i ew  p um p  o c c l u s i o n  a l a rm s ,u n e x p l a i n e d  h y p e r g l y c em i a,  a n d  u n p l a n n e d
i n f u s i o n  s e t  c h a n g e sw ithp a t i e n t s  a t  e a c h  v i s i t .   
I8B-MC-ITSM (b) Clinical Protocol Page 39
LY900014Any interrupti on of  CSII will need to be documented in the eCRF.  When pat ients resum euse of 
pump following the interruption, the infusio n set change shoul d not be entered as an unplanned 
infusio n set change in the study  diary.
9.1.4.4. Diabetes Training
Training will include the following:
Verify Contour Next LINK meter is paired and communicat ing with pump
Frequency of reservoir and infusio n set changes
Frequency of sensor changes
Infusio n site and sensor site rotati on
Responding to pump and sensor alerts and alarms
Unexplained hyperglycemia management
Patient’s abilit y to carb count
Patient’s abilit yuse the pum p’s bol us calculator to determine bolus and correction doses
Patient’s abilit y to use bolus ty pes appropri ately
Patient’s ab ility to treat hy poglycemia
Appropriate site personnel will administer training and educat ion using locally approved diabetes 
education/training materials and programs or by  using other materials that may  be provi ded by 
the sponsor.  Patients may be provid ed addi tional training and educat ion at visits fo llowing 
Visit2, based upon pati ent needs.
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee ofany event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Invest igators must document their review of each lab oratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the IP,the medical 
device or the study procedures that cause d the patient to discont inue the IPbefore complet ing the 
study .  The patientshoul d be f ollowed upuntil the event resolves, stabilizes with appropriate 
diagnosti c evaluat ion, or is reasonably  explained.  The frequency of follow -up evaluat ions of the 
AE is left to the di screti on of  the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the informed consent form ( ICF
)is signed, study site personnel will recor d via electroni c 
data entry  the occurrence and nature of each pat ient’s preexist ing condit ions, including clinically  
significant si gns and symptom s of the disease under treatment in the study .  In addi tion, si te 
personnel will record any  change in the cond ition(s) and any new condit ions as AEs. 
I8B-MC-ITSM (b) Clinical Protocol Page 40
LY900014Invest igators should record their assessment of the potential relatedness of each AE to protocol 
procedure, IP, via electronic data entry . 
The invest igator will interpret and document whether or not an AE has a re asonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment, or pathologies .  
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the IP, 
medical device ,and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s IPis discont inued as a result of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via electroni c data ent ry, clarifying, if possible, the circumstances leading to any  
dosage modificat ions, or discont inuat ions of treatment. 
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospitaliz ation but m ay jeopardi ze the patient or m ay require intervent ion 
to prevent one of the other outcomes listed in the definit ion above.   Examples of 
such m edical events include allergic bronchospasm requiring intensive treatment 
in an em ergency depart mentor at hom e, blood dyscrasias or convulsions that do 
not resul t in inpat ient hospi talizat ion, or the develo pment of drug dependency or 
drug abuse.
Severe hypoglycemic events:  episodes of severe hypoglycemia as determined by 
the invest igator according to the definit ion provi ded in Sect ion 9.4.2 must be 
reported as SAEs
All AEs occurring after signing the ICF are recorded in the case report form ( CRF )and assessed 
for seri ous cri teria.  The SAE reporti ng to the sponsor begins after the patient has signed the ICF 
and has received IP.  However, if an SAE occurs after signing the ICF, but prior to receiving IP, 
the SAE should be reported to the sponsor according to SAE -reporting requirements and 
timelines (see Sect ion 9.2) if it is considered reasonably possibly related to study  procedure.
I8B-MC-ITSM (b) Clinical Protocol Page 41
LY900014Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are i ssued via tel ephone, they  
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow-up SAE 
inform ation.  Patients with a se rious hepat ic AEshoul d have addi tional data collected using the 
eCRF.
Pregnancy (during maternal exposure to IP) does not meet the definit ion of an AE.  However, to 
fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE process to 
collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (the patientdisposit ion CRF has been completed).  
However, if the in vestigator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he or she considers the event reasonably possibly related to 
the study  treatm ent or study  parti cipati on, the investi gator m ust prom ptly not ify Lilly.
9.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to IPor procedure.  United States 21 CFR 
312.32 and European Unio
n Clinical Trial Directive 2001/20/EC and the associated detailed 
guidance or nati onal regulatory  requi rements in parti cipating countri es requi re the reporting of 
SUSARs. Lilly has procedures that will be fo llowed for the ident ificat ion,recording and 
expedited reporting of SUSARs that are consistent with global regulat ions and the associated 
detailed guidance.
9.2.2. Complaint Handling
Lilly co llects product complaints on IP, materials provi ded, and drug delivery  systems used in 
clinical stu dies to ensure the safet y of study  participants, monitor qualit y, and facilitate process 
and product improvements.
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the IPor their insulin pump so that the si tuation can be assessed .  
Any insulin pump issue will be assessed at the investigative site and if not resolved the 
investigator sh ould report the com plaint directly to the pump manufacturer in accordance with 
the product labeling .Investigators should report th ese com plaint s as they  woul d for products in 
the marketplace. 
Com plaint s on IP must be reported to Lilly  by site staff within 24 hours of notificat ion, or 
within 24 hours of study /site personnel  becoming aware of a product issue, regardless of 
the availabilit y of the com plaint sample .  
Invest igative sites must r etain the IP under appropriate storage conditions, if available or 
when obtained, unt il instructed to return it to Lilly .  
I8B-MC-ITSM (b) Clinical Protocol Page 42
LY900014Product complaints for Non -Lilly Products (including concomitant drugs and insulin 
pumps) that do not have a Lilly  Product Batch or Control number are reported direct ly to 
the manufacturer per product label.
Follow the instructi ons outlined in the Product Complaint Form for other report ing 
instructi ons.
9.3. Treatment of Overdose
Excess insulin administration may result in hypoglycemia.  Refer to the IB for LY900014 and 
product label for Hum alog.
9.4. Safety
9.4.1. Hypoglycemia
Patients are encouraged to perform SMBG whenever hy poglycemia may be suspected, ei ther by  
symptoms experienced , CGM reading or perceived increased risk as related to dietary  intake, 
physical act ivity, inadvertent or aty pical  insulin dosing or when prom pted by  pump alerts .  All 
patients will be instructed to consider a BG ≤70 mg/dL to behypoglycemia and treat 
appropriately .
If a hypoglycemi cevent i s suspected, the patientshoul d record the BG value, any associated 
symptoms, and the treatment administered in the study  diary .  The patientshoul d contact the site 
as necessary .  All hypoglycemia events (severe and nonsevere) must be reported on th e 
hypoglycemia eCRF .  All  episodes of severe hypoglycemia must be reported as SAEs on the AE 
eCRF page and on the SAE eCRF page.  Episodes of hypoglycemia not meet ing the criteria for 
severe hypoglycemia should not be reported as an AE.  
Hypoglycemia will be described using the following definit ions:
Documented Glucose Alert (Level 1) ; BG ≤70 mg/dL :
oDocumented symptomatic hypoglycemia :  an event with typical  symptom s of 
hypoglycemia .  
oDocumented asymptomatic hypoglycemia :  an event without typical symptom s 
of hypoglycemia .  
oDocumented unspecified hypoglycemia :  with no informat ion about symptoms 
of hypoglycemia available ( this has also been called unclassifiable 
hypoglycemia) .
Documen ted Clinically Significant Hypoglycemia (Level 2) with similar criterion as 
above except for threshold BG <54 mg/dL 
oDocumented symptomatic hypoglycemia 
oDocumented asymptomatic hypoglycemia
oDocumented unspecified hypoglycemia
Severe Hypoglycemia (Level 3) :  during these episodes, patient shave an al tered m ental  
status and cannot assist in theirown care, may be semiconscious or unconscious, or 
experience co ma wit h or without seizures, an d the event requiring assistance o f another 
person to actively adminis ter carbohy drate, gl ucagon, or other resuscitative act ions.  
Blood gl ucose measurements may not be available during such an event, but neurological 
I8B-MC-ITSM (b) Clinical Protocol Page 43
LY900014recovery  attributable to the restoration of BG concentration to normal is considered 
sufficient evidence that the event was induced by a low BG concentration (BG ≤70 
mg/dL [3.9 mmo l/L]).  
Other Hypoglycemia
oNocturnal Hypoglycemia :  any documented hypoglycemic event ( including 
severe hypoglycemia) that occurs between bedt ime and waking.  
oProbable Symptomatic Hypoglycemia :  an event during which symptoms are 
present, but BG measurement was not reported .  
oOverall (or Total) Hypoglycemia:  this category combines all cases of 
hypoglycemia (documented hypoglycemia andprobable symptom atic
hypoglycemia, including severe hypoglycemia) .  Nocturnal  and severe 
hypoglycemia are special cases of docum ented or probable hypoglycemia . If an 
event of hypoglycemia falls into mult iple subcategories, the event is only counted 
once in this category .
Addit ional analysis o f hypoglycemia events will be conducted using CGM data alone for 
thresho ld BG <50 mg/ dL and <70 m g/dL .
9.4.2. Severe Hypoglycemia
The determinat ion of a hypoglycemic event as an episode of severe hypoglycemia, as defined 
above, is made by the investigator on review of the diary  and in discussio n with the pat ient, 
based upon the medical need o f the pati ent to have required assistance and is not predicated on 
the report of a patient simply having received assistance .
9.4.3. Electrocardiograms
For each patient, ECGs should be performed at Vi sit 1 according to the study -specific described 
in the Schedule of Act ivities (Section 2).
Electrocardiograms will be interpreted by  a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
patientis still present, to determine whether the patient meets entry  criteria and for immediate 
patient management, should any  clinically relevant findings be identifie d.
Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary .
9.4.4. Vital Signs
For each patient, vital sign m easurements shoul d be conducted according to the Schedule of 
Activities (Section 2) including the study -specific requi rements .  
9.4.5. Laboratory Tests
For each patient, laboratory tests detailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Act ivities (Section 2). 
I8B-MC-ITSM (b) Clinical Protocol Page 44
LY900014With the exception o f laboratory  test resul ts that may  unblind the study , Lilly or i ts desi gnee will  
provi de the invest igator with the results of laboratory  tests analyzed by  a central  vendor, if a 
central  vendor i s used for the clinical trial.  
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of IPshoul d be reported to Lilly  or its designee as an AE
via electronic data entry .
9.4.6. Safety Monitoring
Lilly will periodic ally review evolving aggregate safet y data wi thin the study  by appropri ate 
methods.
9.4.6.1. Pilot Safety Assessment
The pilot safet y assessment will take place over 3 days fo llowing rando mizat ion ofthe first 10 
patients at a single site .  During thi s time, pilot patients must have a designated study  companion 
who is familiar with managing T1D ,agree to stay with the pati ent overnight to assi st wi th 
checking night -time BGand troubl eshooting pump al arms .  The designated study  com panion is 
not required to accompany thepatient during day -time hours.   
The invest igative site will check in wit h the patient at Day  1 via a tel ephone call.  During the 
Visit 5 tel ephone call, the invest igator will review patient data and determine if the pat ient can 
continue study  treatm ent.  
For 3 nights fo llowing the rando mization visit (Visit 4), the desi gnated com panionmust;
agree to sleep in the same room with the patient, 
sleep within hearing distance of the CGM and pump alarms, 
be willing to awaken at least once between 2:00 AMand 4:00 AMto assist the pa tient in 
checking BG,  
be willing to assist the patient in troubleshooting an alarm if one should occur during the 
night. 
During the Pilot Safet y Assessment the Invest igative Site will ; 
call each pilot pati ent to check -in within1 day  post randomizat ion visit 
add di ary data to eCRF and run a CareLink report for each pat ient3 days post 
rando mizat ion visit (Visit 5) enabling the site to ; 
oreview hypoglycemia, hyperglycemia ,occlusion alarm  data , and unplanned 
infusio n set changes and reasons   
odiscuss other safet y issues found in review o f SAEs, AEs, Carelink reports, etc.
decide and docum ent if pat ient is to continue in the study . 
Safety Criteria
The fo llowing prespecified criteria will be reviewed by the invest igator , along wi th medical 
judgment to determine if it is safe to proceed with rando mizat ion of addit ional pat ients..  
One episode of severe hypoglycemia 
I8B-MC-ITSM (b) Clinical Protocol Page 45
LY900014More than 1 case of hy perglycemia (BG >300 mg/dL) sustained for more than 2 hours 
and unresponsive to treatment measures
One episode of DKA
Moderate or large urine ketones and BG >300 mg/dL
Expanding the Pilot Safet y Assessment
The pilot safet y assessment may be terminated or may be expanded to further understand how 
LY900014 interacts with the control algorithm in the Medtronic 670G system if any of theabove 
criteria are met or if review of the data collected from SAEs, AEs, Carelink reports, etc .and 
discussio ns wi th patients reveals other safet y issues in the judgment of the invest igator.
Transit ion from Pilot Safet y Assessment to Rest of the Study
Within 1 -week of all 10 pilot patients complet ing the 3 -day pilot safety  assessment, the 
investigators will review the collected data in consultation with the Sponsor and determine if 
rando mizat ion can be opened up for the rest of the study .  The 10 pilot patients will cont inue 
progressing through the study  after com pletion of the pilot safet y assessment so long as they  are 
deem ed fit to continue by  the si te, have had no safety  issues that would warrant discont inuat ion 
from the study , and no deci sion has be en made to halt the study .  No addi tional pat ients will be 
rando mized unt il after a review o f pilot safet y data occurs and it is decided if cont inuing the 
study  is warranted.   Following the pilot safet y assessment, all sites will receive communicat ion 
from the sponsor to begin rando mizat ion of pat ients not participat ing in the pilot safet y 
assessment.
9.4.6.2. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL ≥2X 
ULN, liver testing ( Appen dix 4 ) shoul d be repeated wi thin 3 to 5 days including ALT, AST, 
ALP, TBL, direct bilirubin, gamma -glutamyl  transferase, and cr eatine kinase to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator and in 
consultation wit h the study  medical mo nitor.  Moni toring of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels. 
Hepatic Safety Data Collection
Addit ional safet y data should be co llected via the eCRF if 1 or m ore of the fo llowing condi tions 
occur: 
Elevat ion of serum ALT to ≥5X ULN on 2 or more consecutive blood tests
Elevat ion ofserum  TBL to ≥2X ULN (except for cases of known Gilbert’s 
syndro me)
Elevat ion of serum ALP to ≥2X ULN on 2 or more consecutive blood tests
Patient discont inued from t reatm ent due to a hepatic event or abnormalit y of 
liver tests
Hepati c event consi dered to be a SAE
I8B-MC-ITSM (b) Clinical Protocol Page 46
LY9000149.5. Pharmacokinetics
Not applicable.
9.6. Pharmacodynamics
Not applicable.
9.7. Pharmacogenomics
Not applicable .
9.8. Biomarkers
Not applicable.
9.9. Health Economics
Not applicable.
I8B-MC-ITSM (b) Clinical Protocol Page 47
LY90001410.Statistical Considerations
10.1. Sample Size Determination
Approximately  42patients will be rando mized in order that approximately 36patients com plete 
the study .
Assuming that a standard deviation (SD) of between -period differences of 10% and a 2- sided 
alpha level  of 0.10, 3 6completers will provide approximately 90% power to detect a 5% 
difference between LY900014 and Humal og, in the percentage of time with SGvalues from 70
to180 m g/dL (inclusive) ,during the last 2 weeks of each 4-week treatm ent peri od.  
Assuming a 12% dropout rate after randomization, approximately 4 2patients (2 1patients in each 
sequence) will need to be randomized. 
10.2. Populations for Analyses
For purposes of analysis, the following populat ions are defined:
Population Description
Entered All patients who give informed consent.
Enrolled All patients who receive at least 1 dose of open -label Humalog in the 2-week lead -in 
period.
Randomized All patients who are randomly assigned to study treatment at Visit 4 and receive at least 
1dose of the randomly assigned IP .  Treatment will be defined on the basis of the 
treatment the patients are assigned to.
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the respons ibilit y of Lilly or i ts desi gnee.   Any change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of the protocol.  Any  other change to the data analysis methods 
described in the protocol, and the just ificat ion for making the change, will be described in the 
statist ical analysis plan (SAP) or the clinical study  report (CSR) .  Addit ional exploratory  
analyses o f data will be conducted, as deemed appropriate.   
Unless otherwise specified, all efficacy and safet y analyses will be conducted on the
Randomized Population.Analyses of AEs will include all data collected during the course of the 
entire 4-week treatm ent peri od for each treatm ent regardl ess of IP use.  Analyses of 
hypoglycemia will be conducted from first dose to last dose of IP in each 4-week treatm ent 
period.  Data collected during the safet y follow-up peri od will only be summarized for overall 
and will not be used for comparisons between treatments.   
Unless otherwise noted, all tests of treatment effects will  be conducted at a 2 -sided alpha level o f 
0.10, and confidence intervals ( CIs) will be calculated at 9 0%, 2 -sided.  
I8B-MC-ITSM (b) Clinical Protocol Page 48
LY900014Treatment comparisons will be performed for the primary  object ive (Section 10.3.3.1 ) atthe full 
significance l evel of 0. 10. No mult iplicit y adjustment will be made for secondary  and
exploratory  object ives.
Baseline is defined as the last nonmissing measurement at or before the rando mizat ion visit
(Visit 4), unl ess otherwise spe cified and described in the SAP .
Unless otherwise specified, a restricted maximum likelihood based, mixed -effect m odel repeated 
measures (MMRM) analysis will be used to analyze continuous longitudinal variables.  All the 
longitudinal observations at each scheduled postbaseline visit during the 4-week treatm ent peri od 
for each treatm ent wil l be included in the analysis.  The model will include the fixed class effects 
of treatm ent, peri od, sequence, strata (HbA1c [≤7.0
%, >7. 0%] and percentage of time with SG
values from 70to180mg/dL over the 2 weeks prior to randomization [ ≤75%, > 75%]
), and the 
continuous, fixed covariate of baseline value.  The Kenward- Roger approximat ion will be used 
to estimate deno minator degrees of freedom.   An unstructured covariance structure will be used 
to model the wi thin-patient errors.  If this analysis fails to converge, a covariance structure of 
compound symmetry  without heterogeneous variances will be used. If the model still does not 
converge , strata m
ay be del eted f rom the m odel.  Significance tests will be based on least squares
means and Ty pe III tests.  SAS PROC MIXED will be used to perform the analysis.
For categorical measures (such as inci dence of AEs), summary statist ics will include sample 
size, frequency , and percentages.  Prescott’s exact test will be used for treatment comparisons, 
unless otherwise specified.
10.3.2. Treatment Comparability
10.3.2.1. Patient Disposition
A detailed description o f patientdisposi tion will be provi ded.  Frequency  counts and percentages 
of all pat ients entered, enrolled, rando mized, co mpleting, and/or discontinuing fro m the study  
will be pr esented for overall and by  treatm ent sequence and period. Reasons for discont inuat ion
from the study  during Period I and Period II will be summarized by  treatm ent sequence and 
period.
Reasons for discont inuat ion from the study  during the lead -in and fo llow-up peri ods will  be 
summarized for overall  popul ation.
10.3.2.2. Patient Characteristics
Standard baseline characterist ics of age, sex, ethnicit y, race, hei ght, wei ght, and BMI will be 
summarized for the Rando mized Population and by  treatm ent sequence .  Summary  stati stics will 
include sample size, mean, SD, median, minimum, and maximum for continuous measures and 
sample size, frequency , and percent for categorical measures.  Baseline diabetes characterist ics 
will be s ummarized in a similar manner.
Medical history  and AEs at baseline will be summarized by  preferred term (PT) wi thin system  
organ class (SOC) .  
I8B-MC-ITSM (b) Clinical Protocol Page 49
LY90001410.3.2.3. Concomitant Therapy
The ty pe of rapid -insulin therapy at study entry will be summarized by  treatm ent sequence.  The 
basal and bo lus insulin doses during the lead- in peri od will be also be summarized by treatm ent 
sequence .
Concomitant medi cations used during the treatment period will be summarized and compared 
between treatments using Prescott’s exact test.
10.3.2.4. Treatment Compliance
No specific study  data will be collected for analysis of treatment compliance (as defined in 
Secti on 7.6).  No analyses are planned to assess treatment compliance.
10.3.3. Efficacy Analyses
10.3.3.1. Primary Analyses
The primary  object ive of this study  is to com pare LY900014 and Humal ogwith respect to the 
percentage of time with SGvalues within range (70to 180 mg/dL , both inclusive ), during the 
last 2 weeks of each 4-week treatment period. The analysis model (MMRM ) and selection of 
covari ance structure are described in Section 10.3.1 .
The primary  analyses will  be conducted on data collected fro m the Randomized Population, 
while pat ients are on IP and on pump .  
10.3.3.2. Secondary Analyses
Addit ional continuous secondary  efficacy variables, as well as the change during each 4 -week 
treatm ent peri odfor these variables, will  be analyzed by  the MMRM model described in 
Secti on10.3.1 .
10.3.3.3. Exploratory Analyses
Addit ional continuous exploratory efficacy variables, as well as the change from baseline for 
these variables, will be analyzed by the MMRM model described in Section 10.3.1 , unless 
otherwi se specified.
10.3.4. Safety Analyses
Safety measures will include AEs, 
hypoglycemia, vital signs, treatment exposure, and laboratory  
measures.
Events that are newly  reported after the first dose of rapid -acting insulin provided as study drug 
(i.e., open -label Humal ogused during the lead- in peri od or IP used during each of the two 
4-week randomized treatment periods) or reported to wors en in severit y from baseline (details 
will be described in SAP )will be considered -TEAEs.  Events that continue during more than 1 
study  period (l ead-in, Period I, and Period II) wi th the sam e severi ty will only  be counted once 
for the first study  period.
Serious AEs, AEs reported as reason for discontinuation fro m the IP or study , and TEAEs will be 
summarized in tables using the Medi cal Dict ionary for Regulatory  Activities (MedDRA )PT, 
sorted by  decreasing frequency wit hin the LY900014 treat ed-patients . Treatment -emergent AEs 
I8B-MC-ITSM (b) Clinical Protocol Page 50
LY900014will also be summarized by  PT sorted by  decreasing frequency wit hin SOC for all TEAEs and by 
maximum severit y. For events that are gender -specific (as defined by MedDRA), the 
deno minator and computation of the percentage will inclu de only  patients from the given gender.
The number and proportion of pat ients with at least 1 event for each ty pe of  event will be 
summarized and co mpared between treatment s using Prescott’s exact test.
Hypoglycemia rates will be summarized for periods of 1 y ear, and 100 y ears (severe 
hypoglycemia only ) for both treatm ent peri ods. Wilcoxon Signed -Rank test and Prescott’s exact 
test will be used instead to analyze the rate and incidence o f hypoglycemia ev ents, respectively.
10.3.5. Subgroup Analyses
The fo llowing subgroup will be explored to evaluate consistency  of treatm ent effects on the
primary  endpo int:
Pump bolus delivery  speed at screening (Standard [1.5 U/min], Quick [15 U/min] )
HbA1c stratum ( ≤7.0%,>7.0%) 
Percentage of time with SGvalues from 70to180 over the 2 weeks prior to 
rando mizat ion (≤75%, > 75%)
Addit ional exploratory  subgroup analyses may  be perform ed.
10.3.6. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim a nalysis is deemed 
necessary , the appropri ate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.
I8B-MC-ITSM (b) Clinical Protocol Page 51
LY90001411. References
Albert i KG, Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultation. Diabet Med . 1998;15(7):539 -553.
Battelino T, Con get I, Olsen B, Schütz -Fuhrmann I, Hommel E, Hoogma R, S chierloh U, Sulli 
N, Bolinder J . The use and efficacy  of cont inuous glucose monitoring in t ype 1 diabetes 
treated with insulin pump therapy  [SWITCH study]. Diabetologia. 2012;55(12):3155-3162.
BennettP. Classificat ion and diagnosis of diabetes mellitus and impaired glucose tolerance. In: 
Pickup JC, William G, editors. Textbook of diabetes. Vol. 1. 1st ed. Oxford: Blackwell 
Scientific Publicat ions; 1991:p 37 -44.
Bergenstal  RM, Tamborl ane WV, Ahmann A, Buse JB, Dailey  G, Davis SN, Joy ce C, Peopl es T, 
Perkins BA, Welsh JB, Willi SM, Wood MA . Effectiveness of sensor -augmented 
insulin -pump therapy  in type 1 diabetes [STAR3 Study]. N Engl J Med .2010;363:311 -320.
Bergenstal  RM, Klo noff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ , Welsh 
JB, Lee SW , Kaufman FR . Threshol d-based insulin -pump interruption for reduction of
hypoglycemia [ASPIRE in- home study ]. N Engl J Med . 2013;369(3):224- 232.
[CCNYHA] The Criteria Co mmit tee of  the New York Heart Associa tion. Nom enclature and 
criteria for di agnosis of diseases of the heart and great vessels. 9th ed. Boston (MA): Little, 
Brown & Company; 1994:253-
256.
Stark Casagrande S, Fradkin JE, Say dah SH, Rust KF, Cowie CC. The prevalence of meet ing 
A1C, blood pressure, and LDL goals amo ng people with diabetes, 1988 -2010. Diabetes Care . 
2013;36(8):2271 -2279.
I8B-MC-ITSM (b) Clinical Protocol Page 52
LY90001412. Appendices
I8B-MC-ITSM (b) Clinical Protocol Page 53
LY900014Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event: Any untoward medical occurrence in a patient or clinical investigation patient
administered a pharmaceutical product thatdoes not necessarily have a causal relationship 
with this treatment .  An AEcan therefore be any unfavorable and unintended sig n (including 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.
AIT active insulin time
ALP alkaline phosphatase
ALT alanine aminotransferase
AST aspartate aminotransferase
BG blood glucose
blinding A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the treatment 
but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or sponsor 
staff who are involved in the treatment or clinical evaluation of the patients are aware of the 
treatment received.
CGM continuous glucose monitoring
CI confidence interval
confirmed pump 
occlusionAn interruption in continuous pump insulin flow that triggered an occlusion alarm that would 
not clear, after confirming that the pump and infusion set are in place without leaks or kinks 
in the system.
CR carb ratio
CRF case report form
CRP /CRS clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician ,or other medical officer.
CSII continuous subcutaneous insulin infusion
CSR clinical study report
DKA diabetic ketoacidosis
ECG electrocardiogram
I8B-MC-ITSM (b) Clinical Protocol Page 54
LY900014eCRF electronic case report form
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are those 
who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form directly or through 
their legally acceptable representatives.
ERB ethical review board
GCP good clinical practice
HbA1c hemoglobin A1c
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IP investigational product: A pharmaceutical form of an active ingredient or placebo being 
tested or used as a reference in a clinical trial, including products already in the market when 
used or assembled (formulated or packaged) in a way different from the authorized form, or 
mark eted products used for an unauthorized indication, or marketed products used to gain 
further information about the authorized form.
ISF insulin sensitivity factor
IWRS interactive web -response sy stem
LS least squares
MDI multiple daily injections
MedDRA Medical Dictionary for Regulatory Activities
MMRM mixed-effect model repeated measure
product complaint Product complaints are a customer ’s written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, dura bility, reliability, safety, effectiveness, or 
performance of a Lilly product after it is released for distribution.
PT preferred term
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of a pool 
of potential candidates for participation in a clinical study
SD standard deviation
I8B-MC-ITSM (b) Clinical Protocol Page 55
LY900014SG sensor glucose
SMBG self-monitored blood glucose
SOC system organ class
SUSARs suspected unexpected serious adverse reactions
T1D type 1 diabetes mellitus
T2D type 2 diabetes mellitus
TBL total bilirubin level
TEAE treatment -emergent adverse event:  An untoward medical occurrence that emerges during a 
defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state, which does not necessarily have to have a causal relationship with this 
treatment
ULN upper limit of normal
unexplained 
hyperglycemiaHigh blood glucose that cannot be explained by a missed prior bolus, dietary indiscretion, 
rebound or treatment of hypoglycemia, a pump failure, an empty pump reservoir, an infusion 
set complication (for example, kinked, came out, leaking), or an infusion site complication 
(for example, pain, redness)
I8B-MC-ITSM (b) Clinical Protocol Page 56
LY900014Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests a
Hematology Clinical Chemistry (Serum Concentrations of)
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Total bilirubin
Mean cell volume Direct bilirubin
Mean cell hemoglobin concentration Alkaline phosphatase
Leukocytes (WBC) Alanine aminotransferase (ALT)
Neutrophils, segmented Aspartate aminotransferase (AST)
Lymphocy tes Blood urea nitrogen (BUN)
Monocytes Creatinine
Eosinophils Uric acid
Basophils Calcium
Platelets Chloride
Magnesium
Urinalysis Total protein
Specific gravity Glucose
pH Albumin
Protein Creatin ine kinase (CK)
Glucose
Ketones
Blood 1,5-Anhy droglucitol
Urine leukocyte esterase Hemoglobin A1c
Bilirubin
Nitrite Serology
Pregnancy test (females only) b
Follicle -stimulating hormonec
aAll laboratory tests will be assayed by a Lilly -designated central laboratory, unless otherwise noted.
bSerum pregnancy test must be performed in women of childbearing potential at Visit 1 followed by a urine 
pregnancy test within 24 hours prior to IP exposure at randomization and at other times at the investigator’s 
discretio n.  W hen required per local regulations and/or institutional guidelines, local pregnancy testing will occur 
at mandatory times during the study treatment period.  
cFollicle -stimulating hormone test must be performed at Visit 1 for a postmenopausal woman who is betwee n 
50and 54 years of age (inclusive) with an intact uterus, not on hormone therapy, and who has had at least 
6months of spontaneous amenorrhea.
I8B-MC-ITSM (b) Clinical Protocol Page 57
LY900014Appendix 3. Study  Governance Considerations
I8B-MC-ITSM (b) Clinical Protocol Page 58
LY900014Appendix 3.1.Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 3.1.1 .Informed Consent
The invest igator is responsible for:
ensuring that the patientunderstands the nature of the study , the potential risks 
and benefits of participat ing in the study , and that their participat ion is vo luntary.
ensuring that informed consent is given by each patient or legal representative.  
This includes obtaining the appropriate signatures and dates on the informed 
consent form ( ICF) prior to the performance of any  protocol  procedures and pri or 
to the administr ation of  invest igational product.
answering any quest ions the pati ent m ay have throughout the study  and sharing in 
a timely manner any  new informat ion that m ay be rel evant to the patient’s 
willingness to continue his or her participat ion in the study .
ensuring that a copy  of the ICF is provi ded to the participant or the participant’s 
legal representative and is kept on file.
ensuring that the medical record includes a statement that written informed 
consent was obtained before the participant was enrolled i n the study  and the date 
the wri tten consent was obtained. The authorized person obtaining the informed 
consent must also sign the ICF.
Appendix 3.1.2 .Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for pati ents.  Individual 
investigators may have addit ional local requirements or processes.
Appendix 3.1. 3. Ethical Review
The invest igator must give assurance that the ethical review board (ERB) was pr operly 
constituted and convened as required by Internat ional Council for Harm onisati on (ICH) 
guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begi n at the investigative site(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
theprotocol and related amendments and addenda ,current IB or Pati ent 
Inform ation Leaflet, Package Insert, or Summary  of Product Characterist icsand 
updates during the course of the study
ICF
other relevant docum ents ( for example , curri cula vi tae, adverti sements)
I8B - MC- IT SM  (b )C l in ica l  P ro toco l Page  59
LY900014Append ix  3 .1 .4 . Regu la to ry  Cons ide ra t ions
Th i s  s tudy w i l l  b e  c o n d u c t e d  i n  a c c o r d a n c e  w i t hth e  p r o t o c o l  a n d  w i t h  th e :
 c o n s e n s u s  e t h i c s  p r i n c i p l e s  d e r i v e d  f r o m  i n t e r n a t i o n a l  e t h i c s  g u i d e l i n e s ,  i n c l u d i n g  
th e  D e c l a r a t i o n  o f  H e l s i n k i  a n d  Coun c i lf o rI n t e r n a t i o n a lO rg an i z a t ion so f
M e d i c a lS c i en c e s( C IOMS)  In t e rn a t i on a l  E th i c a l  Gu i d e l in e s
 a p p l i c a b l e  ICH  GCP  G u i d e l i n e s
 a p p l i c a b l e  l aw s  and  r egu l a t ion s
Some  o f  t h e  o b l i g a t i o n s  o f  t h e  s p o n s o r  w i l l  b e  a s s i g n e d  t o  a  t h i r dp a r ty .
Append ix  3 .1 .5 . Inves t iga to r  In fo rma t ion
I n v e s t i g a t o r ( s )  p a r t i c i p a t i n g  in  th i s  s tudy  w i l l :  
 b e  a  p h y si c i a n  w i t h  s p e c i a l t y  i n  E n d o c r i n o l o gy  o r  D i ab e to l ogy  
 h a v ee x p e r i e n c e  w i th  C o n t i n u o u s  S u b c u t a n e o u s  I n s u l i n  I n f u s i on  (CS I I )  a n d  
C o n t i n u o u s  G l u c o s e  M o n i t o r i n g  (CGM )
 h a v e  cl i n i c a l  t r i a l  e x p e r i e n c e
 
A tl a n ta  D i ab e t e s  A s so c i a t e s
1 8 0 0  H ow e l l  M i l l  R d ;  S u i t e  # 4 5 0  
A tl a n ta ,  GA  3 0 3 1 8
I n t e r n a t i o n a l  D i a b e t e s  C e n t e r
3 8 0 0  P a r k  N i c ol l e t  B l v d .
M i n n e a p ol i s ,  MN  5 5 4 1 6
Append ix  3 .1 .6 . P ro toco l  S igna tu res
T h e  s p o n s o r ’ s  r e s p o n s i b l e  m e d i c a l  of f i c e r  w i l l  a p p r o v e  t h e  p r o t o c o l ,  c o n f i rm i n g  t h a t  t o  t h e  b e s t  
o f  h i s  o r  h e r  k n ow l e d g e ,  t h e  p r o t o c o l  a c c u r a t e l y  d e s c r ib e s  th e  p l a n n e d  d e s i g n  a n d  c o n d u c t  o f  t h e  
s tudy .
A f t e r  r e a d i n g  t h e  p r o t o c o l ,  e a c h  p r i n c i p a l  i n v e s ti g a t o r  w i l l  s i g n  t h e  p r o t o c o l  s i g n a t u r e  p a g e  a n d  
s end  a  copy  o f  t h e  s i g n e d  p a g e  t o  a  L i l l y  r e p r e s e n t a t i v e .
Append ix  3 .1 .7 . F ina l  Repo r t  S igna tu rePPD
T h e  i n v e s ti g a t o r  w i l l  s i g n  t h e  f i n a l  c l i n i c a l  s t u d y  r e p o r t  (CSR )  f o r  t h i s  s t u d y ,  i n d i c a t i n g  
ag r e em en t  w i th  t h e  a n a l y s e s ,  r e s u l t s ,  a n d  c o n c l u s i o n s  of  th e  r epo r t .PPD
PPD
PPD
I8B-MC-ITSM (b) Clinical Protocol Page 60
LY900014The sponsor’s responsible medical o fficer and statistic ian will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendi x 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion of the case report 
forms (CRFs ), and study  procedures.
make periodic visit s to the study  site
be available for consultati on and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its represen tatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applic able ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data -capture (EDC) sy stem  will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  the invest igator or 
designee into the sponsor -provided EDC system.  The invest igator is responsible for th e 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported are 
accurate and complete by  signing the CRF.
Addit ionally , clinical  outcom e assessment data (questionnaires and self -reported di ary data) will 
be co llected by the subject, vi a a paper source document and will be transcribed by  the 
investigator -site personnel into the EDC system.
Data collected via the sponsor- provided data capture system will be stored wi th a thi rd party .  
The invest igator will have cont inuous access to the data during the study and unt il 
I8B-MC-ITSM (b) Clinical Protocol Page 61
LY900014decommissio ning of the data -capture system.  Prior to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test d ata, will be stored electronically in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention.  Data will subsequent ly be transferred fro m the central  vendor to the Lilly  data 
warehouse.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its de signee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly or i ts desi gnee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3. 4. Publication Policy
The publicat ion policy for Study  I8B-MC-ITSM is described in the Clinical Trial  Agreement .
I8B-MC-ITSM (b) Clinical Protocol Page 62
LY900014Appendix 4. Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts designee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT =alanine aminotransferase; AST =aspirate aminotransferase; CPK =creatinine 
phosphokinase; GGT =gamma -glutamyl transferase; Ig =immunoglobulin; INR =internatio nal normali zed 
ratio; RBC =red blood cells; WBC =white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I8B-MC-ITSM (b) Clinical Protocol Page 63
LY900014Appendix 5. Classification of Contraceptive Methods
Women of childbearing potential must use either 1 highly effective method of contraception or a 
combinat ion of 2 effect ive methods of contraception.  The patient may choose to use a 
doubl e-barrier method of co ntraception (see chart below).
Barri er protecti on m ethods wi thout concomi tant use of a spermicide are not an effect ive 
or acceptable method of contraception.  Thus, each barrier method must include use of a 
spermicide (that is, condom wit h spermicide, diaphragm wit h spermicide, female condom 
with spermicide).  It should be noted, however, that the use of male and female condoms 
as a doubl e-barrier method i s not considered acceptable due to the high failure rate when 
these barrier methods are combined.
Methods of Contraception
Highly Effective Methods of Contraception Effective Methods of Contraception
(Must Use Combination of 2 Methods )
Combined oral contraceptive pill and mini -pill
NuvaRing ®
Implantable contraceptives
Injectable contraceptives (such as Depo -Provera ®)
Intrauterine device (such as Mirena ®and ParaGard ®)
Contraceptive patch –ONLY women <198 lb.or 90 kg
Total abstinence
Vasectomy Male condom with spermicide
Female condom with spermicide
Diaphragm with spermicide
Cervical sponge
Cervical cap with spermicide
I8B-MC-ITSM (b) Clinical Protocol Page 64
LY900014Appendix 6. Protocol A mmendment I8B-MC-ITSM (b)
Evaluation of LY900014 in a Medtronic Pump
Overview
Protocol  I8B-MC-ITSM (b) Evaluation of LY900014 in a Medtroni c Pum phas been amended.  
The new protocol is indicated by  amendment (b) and will be used to conduct the study  in place 
of any preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protoc ol are described in the 
following table:
Amendment Summary for Protocol I8B-MC-ITSM Amendment ( b)
Section # and Name
Section 6.4 Screen Failures Section 3.3 Benefit/Risk Assessment
Section 5.1 Overall Design
Section 9.4.6.1. Pilot Safety Assessment
Appendix 3.1.5 Investigator Information
Description of Change
Added exception for criteria 11b, 11c and 19. 1. changing “single -center” to “multi -center” 
2. adding single site to all references to the pilot safety 
assessment
3. Deleted Investigator address
Brief Rationale
[11b] and [11c]:  Following a 670G system interruption or 
malfunction, Auto Mode will not activate until the system has 
completed a warm -up period that lasts between 5 and 48 hours 
beginning at midnight after the system is restarted.  If this 
occurs during the 4 weeks prior to screening, the percentage of 
time in Auto Mode and percentage of sensor wear time may be 
negatively impacted.
[19]:  The total daily average dose may exceed 100 units/day 
when carbohydrate consumption is unusually high during the 3 
days prior to screening.Allowing for rescreening of patients for 
whom these criteria apply will potentially increase enrollment 
of qualified study patients.  Lilly believes that allowing these 
patients to rescreen and subsequently be enrolled will not 
negatively impact the study because the initial failure was due 
to a technical or atypical anomaly that has now been corrected.Due to several factors, including enrollment considerations ,the 
protocol is being amended to change from a single -center to a 
multi -center study. Several changes in the text capture this 
transition and also clarify that the pilot safety assessment will 
be performed at only one site .
The implications of the pilot s afety assessment apply to all 
sites. No additional patients will be randomized at any site 
until the decision of whether to continue the study is made and 
communicated across sites.  
Lilly  believes that including additional investigative sites in 
Study  ITRO with expertise in the 670G hybrid closed loop 
system following completion of the pilot safety assessment, 
will expedite enrollment and as well as leverage the experience 
and expertise of multiple investigators. Lilly believes adding 
more sites will not negatively impact the study as the pilot 
safety  assessment will have already been completed at a single 
site, however, the results will apply to all sites involved in the 
study .
I8B-MC-ITSM (b) Clinical Protocol Page 65
LY900014Revised Protocol Sections
Note: Deletions have been ident ified by strikethro ughs.
Addit ions have been identified by  the use of underscore .
Section 6.4 Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
rescreened , .  Retests are also not allowed, except for cases w hen results are not available fro m 
the original sample. with the excepti on of  individuals who screen fail due to; 
Inclusio n
[11] Must be using a Medtronic MiniMed 670G insulin pump 
b)In Auto Mode at least an average of 70% of the time per week 
during the last 4 weeks prior to screening 
c)With a Medtronic Guardian (3) sensor at least an average of 75% 
of the time per week during the last 4 weeks prior to screening
Exclusio n
[19] Have a total  daily  insulin dose >100 units, as determined by the average 
total daily insulin dose over the 3 days prior to screening.  
Or Com binat ion of any above
If an individual screen fails due to one of the reasons listed, the individual may be rescreened 
once, no sooner than 2 week s after the init ial screening.  Patients who rescreen are not eligible to 
participate in the pilot safet y assessment. 
Retests, outside of rescreening, are not allowed, except for cases when results are not available 
from the original sample. It is expected that any  laborprocedure performed in the init ial 
screening berepeated for rescreened patients. 
Synopsis Summary of Study Design
This study  is a prospective, rando mized, double -blind, outpatient, single center, 2-treatm ent 
crossover, active -controlled study  conducted in patients with type 1 diabetes mellitus (T1D) 
currently using an external CSII.  In the 2treatm entperiod s, LY900014 and Humal ogwill be 
delivered via the Medtroni c MiniMed 670G system while in Auto Mode as much as possible.  
Synopsis Treatment A rms and Duration
Following the l ead-in period, a 3 -day pilot safet y assessment will be conducted at a single site
for the first 10 patients rando mized.  This pilot safety assessment will determine if the con trol 
algorithm in the Medtroni c 670G pum p can be used safely  in pat ients receiving LY900014.  
I8B - MC- IT SM  (b )C l in ica l  P ro toco l Page  66
LY900014Sec t ion  3 .3  Bene f i t /R isk  Assessmen t
F ol l o w ing  th e  le a d - i n  p e r i o d ,  a  3 - d a y  p i l o t  s a f e ty  a s s e s sm en t  w i l l  b e  condu c t ed  a t  a  s i n g l e  s i t e
f o rth e  f i r s t  1 0  p a t i e n t s  r a n d om i z e d .   T h i s  p i l o t  s a f e t y  a s s e s sm e n t  w i l l  d e t e rm i n e  i f  t h e  c o n t r o l  
a l go r i thm  i n  th e  M ed t ron i c  670G  pum p  c an  b e  u s ed  s a f e ly  i n  p a ti e n ts  r e c e i v i n g  LY 9 0 0 0 1 4 .   
Sec t ion  5 .1  Ove ra l l  Des ign
Th i s  s tudy i s  ap r o s p e c t i v e ,  r a n d om i z e d ,  d o u b l e- b l ind ,  ou tp a t i en t ,  s i n g l e - c en t e r ,2 - t r e a tm e n t  ,  
c r o s s o v e r ,  a c t i v e - con t ro l l ed  s tudy  condu c t ed  in  p a t i en t s  w i th  T1D  cu r r en t ly  u s i n g  a n  e x t e r n a l  
CS I Ip um p.   In  th e  2t r e a tm en t  p e r i od s ,  LY 9 0 0 0 1 4  a n d  Huma l ogw i l l b e  d e l iv e r ed  v i a  t h e  
M ed t ron i c  M in iM ed  670G  sy s t em w i th  Sma r tGu a rd™  t e c h n o l o gyu s ing  Au toMod e .   I n  t h i s  
s tudy ,  p a t i en t s  w i l l  b e  r equ i r e d  t o  u s e  t h e  A u t o  M o d e  i n s u l i n  d e l i v e r y  f u n c ti o na s  m u c h  a s  
p o s s i b l e .   
F ol l o w ing  th e  le a d - i n  p e r i o d ,  a  3 - d a y  p i l o t  s a f e ty  a s s e s sm en t  w i l l  b e  condu c t ed  a t  a  s i n g l e  s i t ei n  
th e  f i r s t  1 0  p a t i e n t s  r a n d o m i z e d .   T h i s  p i l o t  s a f e t y  a s s e s sm e n t  w i l l  d e t e rm i n e  i f  t h e  c o n t r o l  
a l go r i thm  i n  th e  M ed t ron i c  670G  pum p  c an  b e  u s ed  s a f e ly  i n  p a ti e n ts  r e c e i v i n g  LY 9 0 0 0 1 4 .   
Sec t ion  9 .4 .6 .1  P i lo t  Sa fe ty  Assessmen t
T h e  p i l o t  s a f e ty  a s s e s sm e n t  w i l l  t a k e  p l a c e  o v e r  3  d a y s  f ol l o w i n g  r a n d om i z a ti o n  o f  th e  f i r s t  10  
p a t i en t sa t  a  s i n g l e  s i t e .   
No  add it i on a l  p a t i e n ts  w i l l  b e  r a n d o m i z e d  u n ti l  a f t e r  a  r e v i ew  o f  p i l o t  s a f e t y  d a t a  o c c u r s  a n d  i t  i s  
d e c i d e d  i f  c o n ti n u i n g  t h e  s t u d y  i s  w a r r a n t e d .   F o l l ow i n g  th e  p i l o t  s a f e ty  a s s e s sm en t ,  a l l  s i t e s  w i l l  
r e c e i v e  c o mm u n i c a ti o n  f r om  t h e  s p o n s o r  t o  b e g i n  r a n d o m i z a ti o n  o f  p a ti e n ts  n o t  p a r t i c i p a t i n g  i n  
th e  p i l o t  s a f e t y  a s s e s sm en t .
Append ix  3 .1 .5.  Inves t iga to r  In fo rma t ion
I n t e r n a t i o n a l  D i a b e t e sC en t e r
3 8 0 0  P a r k  N i c ol l e t  B l v d .
M i n n e a p ol i s ,  MN  5 5 4 1 6PPD
PPD
PPDLeo Document ID = bbac6bf0-e0e0-4d17-b834-02fef40fa4dc
Approver: 
Approval Date & Time: 12-Apr-2019 20:04:25 GMT
Signature meaning: Approved
Approver:
Approval Date & Time: 13-Apr-2019 23:21:49 GMT
Signature meaning: ApprovedPPD